Note: Descriptions are shown in the official language in which they were submitted.
~i8(~17~
- 1 - 22749-319 G
DN 73~6B DIV IV
This is a divisional application of Application Ser~
No. 488,073 filed August 2, 1985.
The parent application relates to compounds of the
formula I described hereinafter.
This divisional applicaiton relates to certain novel
compounds of the formula IlIdescribed hereinbelow, which them-
selves have analgesic activities and also are useful as inter-
mediates ~or producing the compounds of the formula I of the
parent application.
Thus an aspect of this d.ivisional application provi-
des a compound o:E the formula:
4 ~ , ~ R2 (III)
[wherein: Alk-N=B
R2 is hydrogen, lower-alXyl, chloro, phenyl or benzyl (or
phenyl or benzyl substituted by from one to two substituents
selected from halo, lower-alkyl, lower-alkoxy, hydroxy, amino,
lower-alkyl.mercapto, lower-alkyl-sulfinyl or lower-alkylsul-
fonyl);
R4 is hydrogen or from one to two substituen-ts selected
from lower-alkyl, hydroxy, lower-alkoxy or halo in the 4-, 5-,
6- or 7- positions;
Alk is ~,~-lower-alkylene having the formula (CH2)n
where n is an integer from 2 to 6, or such lower-alkylene subs-
tituted on the ~- or the ~-carbon a-tom by a lower-alkyl group;
and
N=B is azido, amino, N-lower-alkylamino, N,N-di-
lower-alkylamino, N-(hydroxy-lower-alkyl)amino, N,N-di(hydroxy-
lower-allcyl)amino, N-lower-alkyl-N-(hydroxy-lower-alkyl)amino,
~`
~2~ 17~
- la - 22749-319 G
N-(lower-alkoxy-lower alkyl)amino, N-(halo-n-propyl)amino,
4-morpholinyl, 2-lower-alkyl-4-morpholinyl, 2,6-di-lower-
alkyl-4-morpholinyl, 4-thiomorpholinyl, ~-thiomorpholinyl-S-
oxide/ 4-thiomorpholinyl-S,S-dioxide, l-piperidinyl, 3- or
4-hydroxy-1-piperidinyl, 3- or 4-lower-alkanoyloxy-1-piperi-
dinyl, 3- or 4-a~ino-1-piperidinyl, 3- or 4-(N-lower-alkanoyl-
amino)-l-piperidinyl, 2-cyclohexylmethyl-1-piperidinyl,
l-pyrrolidinyl, 3-hydroxy-1-pyrrolidinyl, l-azetidinyl, l-pipe-
razinyl, 4-lower-alkyl-1-piperazinyl, 4-lower-alkanoyl-1--piper-
azinyl, 4-carbo-lower-alkoxy-1-piperazinyl, hexahydro-4H-1,4-
diazepin-4-yl or the N=B N-oxide thereof] or an acid-addition
salt thereof.
Another aspect of this application provides a process
for preparing the compound of the formula ~III). This process
comprises: reacting a 2-R2-indole of the formula
4 ~ ~ (IV)
(wherein the symbols are as defined above) with an amino-lower~
alkyl halide of the formula
X-Alk-N=B
(wherein X is halogen and the other symbols are as defi.ned
above), in the presence of an acid acceptor, or by reacting a
2-R2-indole of the formula (IV) with an appropriate halo-
lower-alkanamide of the formula
X-Alk'-CO-N=B
(wherein X is halogen, Alk' is an alkylene group as defined for
Alk but having one fewer carbon atoms in its main chain and N=B
is as defined above), in the presence of a strong base, and
reducing the resulting 2-R2~1H-indol-l-alkanamide o-f the
7~
- lb - 22749-319G
formula
4 ~ N~ 2 (V )
Alk ' -CO-N=B
(wherein the symbols hav~ the meanings oE the starting mate-
rials) with lithium aluminum hydride.
A further aspect of this application provides a phar-
maceutical composition comprising an analgesic effec-tive amount
of a compound of the formula (III) as deEined above or a phar-
maceutically acceptable acid-addition salt thereof in admi~ture
with a pharmaceutically acceptable carrier or diluent.
In the following description, it should be understood
that the expression "this invention" includes the subject
matters o this divisional application, of the parent applica-
tion and other divisional applications Eiled from the same
parent application.
~5l3~7~ .~
- lc - 22749-319G
BACKGROUND OF THE INVENTION
~a) Field of the Invention:
This invention relates to 3-arylcarbonyl- and 3-
cycloalkylcarbonyl-l-aminoalkyl-lH~indoles which are use-
~ulasanalgesic,anti-rlleumatlcandanti-inflammatoryagents
~b) In~orm~tion Disclosure Statement:
Deschamps et al~ U.S. Patent 3,946,02~ discloses
compounds having the formula:
~-R3
A-N _R4
~R5
where, inter alia, A is alkylene R2 is one to four carbon
alkyl; R3 i5 a 2-~ 3- or 4-pyridyl group; and R4 and R5 are
joined together to form, with the nitrogen atom, a
piperidino, pyrrolidino or morpholino group. The compounds
are said to possess fibrinolytic and anti inflammatory
actlvities.
Essentially the same disclosure is found ;n Inion
et alO, Eur. JO of Med. Chem., 10 (3), 276-285 (1975).
Speci~ically disclosed in both these references i5 the
species, 2-isopropyl-3-t3-pyridylcarbonyl)~ [2-~4-morpho-
linyl)ethyl]indole.
u . ~
~251~3~7~
--2--
Herbst U.S~ Patent 3,439,770 generically discloses
compounds having the formula:
~1N~
~2
where, inter alia, Rl is "diloweralkylamino, pyr~olidinyl,
piperidino and morpholino and R2 is . .. cyclo~lower)alkanoyl
and adamantanylcarbonyl". Although not within the ambit
of the above-defined genus, the Herbst patent also discloses
a variety of species where R2 is an arylcarbonyl group.
Specifically disclosed, for example, is the species "l-p-
~chlorobenzoyl)-3-~2-morpholinoethyl)indole". The
compounds are said to possess anti-inflammatory, hypo-
tensive, hypoglycemic and CNS activities.
Tambute, Acad. Sci. Comp. ~end., Ser. C, 278 (20),
1239-1242 ~1974) discloses compounds of the formula:
~c6~
~ CH2 ) n~N~ ~
;~ where n is 2 or 3. No utility for the compounds is given.
SUMMARY
In a composition of matter aspect, the invention
relates to 2-R2-3-R3-carbonyl-1-aminoalkyl-lH-indoles and
their acid-addition salts which are useful as analgesic,
anti-rheumatic and anti-inflammatory agents.
i 3 ~
~'æ5~qQ,
In a second composition of matter aspect, the inven-
tion relates to 2-R2-3-R3-carbonylindoles useful as inter-
mediates for the preparation of said 2-R2-3-R3-carbonyl-1-
aminoalkyl-lH-indoles. Certain of the 2-R2-3-R3-carbonyl-
indoles are also useful as anti-rheumatic agents.
In a third co~position of matter aspect, the invention
relates to 2-R~-l-aminoalkyl-lH-indoles also useful as
intermediates for the preparation of said 2-R2-3-R3-
carbonyl-l-aminoalkyl-lH-indoles. Certain of the 2~R2-1-
10 aminoalkyl-lH-indoles are also useful as analgesics.
In a process aspect, the invention relates to a
process for preparing 2-~2-3-R3-carbonyl-1-aminoalkyl~
lndoles which comprises reacting a 2-R2-3-R3-carbollyl-
indole with an aminoalkyl halide in the presence of an
15 acid-acceptor.
In a second process aspect, the invention relates
to a process for preparing 2-R2-3-R3-carbonyl-1-amino-
alkyl-lH-indoles which comprises reacting a 2-R2-1-amino-
alkyl-lH-indole with an arylcarboxylic acid halide or a
20 cycloalkanecarboxylic acid halide in the presence of a
Lewis acid.
In a third process aspect, the invention relates
to a process for preparing said 2-R2-3-R3-carbonyl-1-
aminoalkyl-lH-indoles which comprises reacting a 2-R2-3~
25 R3-carbonyl-1-tosyloxyalkyl- or l-haloalkyl-lH-indole with
an amine.
In a method aspect, the invention relates to a
method of use oE the said 2-R2-3-R3-carbonyl-1-aminoalkyl-
lH-indoles for the relief of pain or of rheumatic or
30 inflammatory conditions
~ ~5 ~ ~ 7 ~
In a second method aspect, the invlention relates to
a method of use of the said 2-R2-3-R3-carbonylindoles Eor
the relief of rheumatic conditions.
In a third method aspect, the invention relates to a
method of use of the said 2-R2-1-aminoalk~yl-lH-indoles for
the relief of pain.
DETAILED DESCRIPTION 3F THE PREFERRl~D EMBODIME:NTS
More specifically, the invention relates to 2-R2-3-
R3-carbonyl-1-aminoalkyl-lH-indoles, which are useful as
analgesic, anti-rheumatic and anti-inflammatory agents,
having the formula:
4 ~ N ¢ ;
Alk-N=B
where:
R2 is hydrogen, lower-alkyl, chloro, phenyl or
benzyl (or phenyl or benzyl substituted by from one
to two substituents selected from halo, lower-
alkyl, lower-alkoxy, hydroxy, amino, lower-alkyl-
mercapto, lower-alkylsulfinyl or lower-alkyl-
sulfonyl);
R3 is cyclohexyl, lower-alkoxycyclohexyl,
phenyl (or phenyl substituted by from one to two
substituents selected from halo, lower-alkoxy,
hydroxy, benzyloxy, lower-alkyl, nitro, amino,
lower-alkylamino, di~lower-alkylamino, lower-
alkoxy-lower-alkylamino, lower-alkanoylamino,
benzoylamino, trifluoroacetylamino, lower-allcyl~
~2~ 0
L~ . Ii . i .S j ~ B
sulonylamino, carbamylamino, lower-alkylmercapto,
lower-alkylsulf;nyl, lower-alkylsulfonyl, cyano,
formyl or hy~lr.oxyiminometllyl),methylenedioxyphenyl,
3- or 4-hydroxy-1-piperidinylphenyl, l-piperazinyl-
phenyl, (l~-imidazol-l-yl)phenyl,(l-pyrrolyl)-
phenyl, anlinomethylphenyl, guanidinylmethylphenyl,
N-cyanoguanidinylmethylphenyl, styryl, lower-alkyl-
substituted-styryl, fluoro-substituted-styryl, 2
or 4-biphenyl, 1- or 2-naphthyl (or 1- or 2-naphthyl
substituted by from one to two substituents selected
from lower-alkyl, lower-alkoxy, hydroxy, bromo,
chloro, fluoro, lower-alkoxycarbonyl, carbamyl,
cyano, lower-alkylmercapto, lower-alkylsulEinyl,
lower-alkylsulfonyl or trlfluoromethyl), thienyl,
furyl, benzo[b~furyl, benzo[b]thienyl, quinolyl or
(N-lower-alkyl)pyrrolyl
R~ is hydrogen or from one to two substituents
selected from lower-alkyl, hydroxy, lower-alkoxy or
halo in the 4-, 5-, 6- or 7- positions;
C=Z is C=O or C=NOH;
Alk is ~w-lower-alkylene having the formula
(CH2)n, where n is an integer from 2 to 6, or such
lower-alkylene substituted on the ~- or the ~-carbon
: atom by a lower-alkyl group; and
. N=B is azido, amino, N lower-alkylamino, N,N-
di-lower-alkylamino, N-(hydroxy-lower-alkyl)amino,
N,N-di-(hydroxy-lower-alkyl)amino, N-lower-alkyl--N-
(hydroxy-lower-alkyl)amino, N-(lower-alkoxy lower-
alkyl)amino, N- (halo-n-propyl)amino~ ~-morpholinyl,
2-lower~alkyl-4-morpholinyl, 2,6 di-lower-alkyl-4-
8~
- 6 - 227~9-319
morpholillyl, 4-tlliomorpholinyl, 4-thiomorpholinyl-S-oxide~
4-thiomorpholinyl-S,S-dioxide, l-piperidinyl, 3- or 4-hydroxy-
l-piperidinyl, 3- or 4-lower-alkanoyloxy-l-piperidinyl, 3- or
4-amino-l-piperidinyl, 3- or 4-(N-lower-alkanoylamino) l-
piperidinyl, 2-cyclohexylmethyl-l-piperidinyl, l-pyrrolidinyl,
3-hydroxy-l-pyrrolidinyl, l-azetidinyl, l-piperazinyl, 4-lower-
alkyl-l piperazinyl, 4-lower-alkanoyl-l-piperazinyl, ~-carbo-
lower-alkoxy-l-pip~razinyl, hexahydro-411-1,4-diazepin-~-yl or
the N=B N-oxides ~hereof, with the proviso -that N=B is not
amino, when R2 is methyl, R3 is phenyl, R~ is hydrogen and Alk
is (C112)3.
PreEerred compounds o~ Eormula I above are those
where:
R2 is hydro~3en or lower-alkyl;
R3 is phenyl, chlorophenyl, fluorophenyl, dichloro-
phenyl, diEluorophenyl, lower-alkoxyphenyl, di-lower-alkoxy-
pllenyl, hydroxyphenyl, lower-alkylphenyl, aminophenyl, lower-
alkylaminophenyl, lower-alkanoylaminophenyl, benzoylaminophenyl,
trifluoroacetylaminophenyl, lower-alkylmercaptophenyl, lower-
alkylsulfinylphenyl, lower-alkylsulfonylphenyl, cyanophenyl,
aminomethylpl1enyl, styryl, 2- or 4-biphenyl, l- or 2-naphthyl
~or l~ or 2-naphtllyl substitu-ted by lower-alkyl, lower-alkoxy,
hydroxy, bromor chloro or fluoro), 2-thienyl, 2-, 3-, 4- or
5-ben~o[bJfuryl, 2-, 3-, 4- or S-benzo~b]thienyl or 2- or 3-
(N-lower-alkyl)pyrrolyl;
R4 is hydrogen or lower-alkyl, lower-alkoxy, fluoro
or chloro in the ~-, 5-, 6- or 7-positions;
~2$~70 D N 356A
--7--
C=Z is C=O;
Alk is 1,2-ethylene t-CH2CH2-), :L-lower-allcyl-l,
2-ethylene (-CHRCH2-), 2-lower-alkyl-1,2-ethylene
(-C~2CHR-), where R is lower-alkyl, 1,3-
propylene (-C~2~H2CH2-) or 1,4-buty:Lene; and
N=B is 4-morpholinyl, 3~ or 4-hydro~y-1-piperi-
dinyl, l-pyrrolidinyl, 3-hydroxy-1-pyrrolidinyl,
N-lower-alkylamino, N,N-di-lower-alkylamino, N,N-
di-(hydro~y-lower-alkyl)amino, l-piperazinyl, 4-
lower-alkyl-l-piperazinyl or 4-lower-alkanoyl-1-
piperazinyl.
Particularly preferred compounds of formula
within the ambit of the invention as defined above are
those where: .
R~ is hydrogen or lower-alkyl;
R3 is phenyl, chlorophenyl, fluorophenyl,
difluorophenyl, lower-alkoxyphenyl, lower-alkyl-
phenyl, aminophenyl, lower-alkylaminophenyl, lower
alkanoylaminophenyl, trifluoroacetylaminophenyl,
lower-alkylmercaptophenyl, lower-alkylsulfinyl-
phenyl, aminomethylphenyl, 1- or 2-naphthyl (or 1-
or 2-naphthyl substituted by lower-alkyl, lower-
alkoxy, hydroxy, bromo, chloro or fluoro), 2-
thienyl, 2-, 3-, 4- or 5-benzolb]furyl or 2-, 3-, 4-
or 5-benzo[b]thienyl;
R4 is hydrogen, lower alkoxy, fluoro or chloro
in the 4-, 5-, 6- or 7-positions;
C-z ls C=O;
Alk is 1,2-ethylene, 2-lower-alkyl-1,2-ethylene,
1-lower-alkyl-1,2-ethylene, 1~3-propylene or 1,4-
butylenes and
25~7a~ ~
N=~ is 4-morpholinyl, 3- or 4-hydroxy-1-
piperidinyl, l-pyrrolidinyl, 3-hydroxy-1-
pyrrolidinyl, N,N-di-lower-alkylamino, N,N-di-
thYdroxy-lower-alkyl)amino~ l-piperazinyl or 4-
lower alkyl-l-piperazinyl.
Other preferred compounds of forrnula I within
the ambit of the invention as defined above aze those
where: -
. R2 is hydrogen or lower-alkyl;
R3 is phenyl, fluorophenyl, chlorophenyl, di-
chlorophenyl, lower-alkoxyphenyl, di-lower-alkoxy-
phenyl, hydroxyphenyl, lower-alkanoylaminophenyl,
benzoylaminophenyl, lower-alkylsulEonylphenyl,
cyanophenyl, styryl, l~naphthyl, lower-alkoxy-
substituted-l- or 2-naphthyl~ 3-benzolblthienyl or
2- or 3-(N-lower-alkyl)pyrrolyl;
R4 is hydrogen or lower-alkyl, lower-alkoxy,
fluoro or chloro in the 4-, 5-, S- or 7-positions;
C=Z is C=O;
Alk is 1,2-ethylene, 1-lower-alkyl-1,2-
ethylene, 2-lower-alkyl-1,2-ethylene, 1,3-propyl-
lene or 1,4-butylene; and
N=B is 4-morpholinyl or 1-pyrrolidinyl.
Still other preferred compounds oE formula I within
the ambit of the invention as defined above are those where:
R2 is hydrogen, lower-alkyl or phenyl;
R3 is cyclohexyl, lower-alkoxycyclohexyl,
phenyl, fluorophenyl, lower-alkoxyphenyl, lower-
alkoxy-fluoeophenyl, benæyloxyphenyl, methylene-
dioxyphenyl, lower-alkylphenyl, di-lower-alkyl-
phenyl, lower-alkylsulfonylaminophenyl, carbamyl-
~2~ 7~
g
aminophenyl, cyanophenyl, formylphenyl, oximino-
methylenephenyl, (l-pyerolyl)phenyl, guanidinyl-
methylphenyl, N-cyanoguanidinylmethylphenyl, 2-
naphthyl, 2-furyl or 2-benzo[b]thienyl;
R4 is hydrogen or lower-alkyl, hydroxy or
lower-alkoxy in the 4-, S-, 6- or 7-positions;
C=z is C=O or C=NOH;
Alk is 1,2-ethylene or 1-lower-alkyl-1,2-ethyl~
eneJ and
N=B is 4-morpholinyl, l-piperidinyl or 1-
pyrrolidinyl or the N-oxides thereof.
Also considered to be within the ambit of the
invention are species having the formulas Ia and Ib:
o
~/ ~ CH-CHC~R3
R4~ N ~l R2
~l k-N=B
Ia
4~ C2R3
CH2CHCH2 -N=B
OH
Ib
where R2, R3, R4, Alk, Z and N=B have the meanings given
. above.
As used herein, unless specifically defined other-
wise, the terms lower-alkyl, lower-alkoxy and lower-
alkanoyl mean monovalent, aliphatic radicals, including
.
7~ _
- 10 - 2~749-319
branched chain radicals, of from one to about four carbon atoms,
for exarnple, methyl, ethyl, propyl, isopropyl, butyl, sec.-
~utyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec.-
butoxy, Eormyl, acetyl, propionyl, butyryl and isobutyryl.
~ s used herein, the term cycloalkyl means saturated
alicyclic groups having Erom three to seven ring carbon atoms,
including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
cycloheptyl.
As used herein, the term halo means fluoro, chloro or
bromo.
In one method, the compounds of formula I where C-Z
i9 C=O are prepared by reacting ~ 2-R2-3-R3-carbonyl-1ll-indole
of formula II witll an amino-lower-alkyl halide amino-~ower-alkyl
tosylate in the presence of an acid-acceptor:
R4 ~ X-Alk-N=~ ~ ~ CO-R
¦ Alk-N=B
~1 I
II (C=Z is C=O)
where R2, R3, R~, Alk and N=B have the meanings given above ancl
X represents halogen or tosyloxy. The reaction is preEerably
carried out in an organic solventinert under the conditions of
the reaction such as dimethylformamide (hereinaEter DMF),
dimethylsulEoxide (hereinafter DMS0), a lower-alkanol or
acetonitrile. Suitable acid-accep-tors are an alkali metal
carbonate, such as sodium carbonate or potassium carbonate, or
an alkali metal hydride, such as
L` o 7 j jb-~
~2$~
--11--
sodium hydride, an alkali metal amide, such as sodamide, or
an alkali metal hydroxide, such as potassium hydroxide.
Preferred solvents are DMF and DMSO, and preEerred acid-
acceptors are sodium hydride, potassiurn carbonate and
potassium hydroxide. The reaction i5 carried out at a
temperature in the range from around 0C. to the boiling
point of the solvent used.
The 2-R2-3-R3-carbonyl-lH-indoles of formula II
are in turn prepared by reacting a 2-R2-indole with a
lower-alkyl magnesium halide and reacting the resulting
Grignard with an appropriate R3-carboxylic acid halide.
The reaction is carried out in an organic solvent inert
under the conditions of the reaction, such as dimethyl
ether, dioxane or tetrahydrofuran (hereinafter TI-IF), at a
temperature in the range from -5C to the boiling point of
the solvent used
Certain compounds within the ambit of formula
II, namely those of ormula II':
R' ~ CO-R3'
II'
where R2 is hydrogen, lower-alkyl or phenyl; R3' is fluoro
phenyl, difluorophenyl, lower-alkoxyphenyl, di-lower-
alkoxyphenyl, lower-alkoxy-fluorophenyl, methylene-
dioxyphenyl, aminophenyl, cyanophenyl, 2- or 4-biphenyl,
1- or 2- naphthyl or lower-alkoxy-substituted-l- or 2-
naphthyl; and R~ is hydrogen or 1uoro are novel species
and comprise a further composition aspect of this inven-
tion.
. , .
-12-
In another method, the compounds of formula I where
C=Z i5 C-O are prepared by reacting a 2-R2-1-aminoalkyl-lH-
indole o formula III wlth an appropriate R3-carboxylic
acid halide (R3-CO~X) in the presence of a Lewis acid, such
as aluminum chloride, and in an organic solvent inert under
the conditions of the reaction. Suitable solvents are
chlorinated hydrocarbons such as methylene dichloride
(hereinafter MDC) or ethylene dichloride ~hereinafter
EDC)~ The reaction is carried out at a temperature Ero~
O~C, to the boiling point of the solvent used. The method
is illustrated by the reaction:
4 ~ ~ ~ ~3-co-x R4- ~ ORR3
Alk-N=B Alk-N=B
III I
(C=Z is C=O)
where R2, R3, R4,Alk, N=B and X have the meanings given above
The intermediate 2-R2-1-aminoalkyl-lH-indoles of
formula III wherein R2, R4 r Alk and N=B have the previously
given meanings comprise yet a further composition aspect of
the present invention. These compounds are prepared by one
of two methods. In one method, a 2-R2-indole of formula IV
is reacted with an amino-lower-alkyl halide in the presence
of an acid-acceptor, in an organic solvent inert under the
conditions of the reaction using the same conditions de-
scribed above for the preparation of the compounds of for-
mula I by alkylation of the compounds of formula II.
In a second method, a 2~R2-indole of formula IV is
reacted with a halo lower-alkanamide in the presence of a
~i;8~7~
-13-
strong base, and the resulting 2-R2-lH-indole-1-alkanamide
of Eormula V is then reduced with lithium aluminum hydride.
The reaction of the 2-R2-indole of formula IV with the
halo-lower-alkanamide is carried out in an appropriate
organic solvent, such as DMF, at a temperature from -5C.
to about 50~C. The reduction of the amides of formula V
with lithium aluminum hydride is carried out in an inert
organic solvent, such as diethyl ether, THF or dioxane, at
a temperature from 5C. to about 50C. The t~o methods
are illustrated by the following reaction sequence:
4 ~ R2
IV ~
Alk-N=B
III
., ,~ /
N ~ R2
Alk'-CO-N=B
V
where R2, R4, Alk and N=B have the meanings given above,
and Alk' is lower-alkylene having the formula (CH2)n,,
where n' is an integer from 1 to 5 or such lower-alkylene
group substituted on the ~carbon atom by a lower-alkyl
group.
In another method for preparing the compounds of
formula I where C-Z is C-0, a 2-R2-3-R3-carbonyl~ (2-
76~
14- 22749-319G
tosyloxy-lower-alkyl~- or (2-halo-lower-alkyl)~lH-indole of
formula VI is reacted with a molar equivalent amount of an
amine, H-N=B, in an organic solvent inert under the con-
ditions of the reaction, such as ace~:onitrile, a lower-
alkanol or DMF. The reaction is preferably carried out by
heating a solution of the reactants at the boiling point of
the mixture. The method is illustratecl by the reaction.
4 ~ ~ ~ ~ HN=B ~r- R4- ~ CO-R3
Alk-X' Alk-N=B
VI
where R2, R3, R4 and N=B have the meanings given above,
and X' represents a toluenesulfonylox~ or halo group
The 2-R2-3-R3-carbonyl-1~2-tosyloxy-lower-alkyl)-
or l-(2-halo-lower-alkyl)-lH-indoles of formula VI, where
Alk is 1,2-ethylene, are in turn prepared by reaction oE a
2 R2-3-R3-carbonyl-indole of formula II with a lower-alkyl
lithium, for example n-butyl lithium, in an inert organic
solvent, such as THF, dioxane or diethyl ether, ollowed by
reaction of the resulting lithium salt with ethylene oxide.
Reaction of the resulting 2-R2-3-R3-carbonyl-1-(2-hydroxy-
ethyl)-lH-indole with toluenesulfonyl chloride in the
presence of an acid-acceptor affords the 1-~2-tosyloxy-
ethyl)-lH-indoles, while reaction of the product with a
phosphorus trihalide affords the corresponding l-(2-halo-
ethyl)-lH-indoles.
The 2-R2-3-R3-carbonyl-1-~2-halo-lower-alkyl)-lH-
indoles of formula VI, where Alk has the other possible
meanings, are prepared by reaction o a 2-R2-3-R3-carbonyl
i
--15--
indole o formula II with an ~ dihalo-lower-alkane ;n the
presence oE a strong base, such as sodium hydride in an
inert organic solvent, such as DMF. The reaction generally
occurs at ambient temperature.
The compounds of formula Ia are prepared by reaction
ofa2-R2-3-formyl-1-aminoalkyl-lH-indolewithanappropriate
methyl R3 ketone according to the reaction:
~ C~O ~ CH=CHC-R3
4 ~ ~ ~ 3 33_ 4 ~ N ¢ R2
Alk-N=B Alk-N=B
where R2, R3, R~, Alk and N=B have the meanings
given above. The reaction is carried out in the presence
of a mineral acid and in an organic solvent inert under
the conditions of the reaction. Preferred solvents are
lower alkanols, such as methanol or ethanol.
The compounds of Eormula Ib, where Z is C=O,
are prepared by reaction of a 2-R2-3-R3-carbonylindole
of formula II with an epihalohydrin in the presence of
a strong base, such as an alkali metal hydride, in
an inert solvent, such as DMF or DMSO, and reaction
oftheresulting2-R2-3-R3 carbonyl-1-[1-(2,3-epoxy)propyl]-
lH-indole with an appropriate amine, H-N=B, according
to the reac~ions:
.
Gl3
-- ~2~ 7~ -
-16-
4~_ + XCH~CH-C112 R4-~ 3~¢
CH 2CH-~ H 2
II ,~
R2
CH2~ HCH2-N=B
Ib OH
where R2, R3, R~, Alk and N=B have the meanings yiven above.
Another method for preparing the compounds of
formula I where R4is 5-hydroxyand C=Z is C=O comprises
reacting benzoquinone with an appropriate N~ lk-N=B) -N-
~l-R2-3-oxo~3-R3-propenyl)amine of formula VII in an
inert, water immiscible or~anic solvent, such as nitro-
methanec The N-(N=B-alkyl)-N-~l-R2-3-oxo-3-R3-propenyl)-
amine in turn is prepared by reaction of a 1,3-diketone,
R2COCH2COR3, with an appropriate aminoalkylamine, B=N-Al};-
NH2 under dehydrating conditions. The reaction is
preferably carried out by heating a solution of the
reactants in an inert, water immiscible solvent under a
Dean-Stark trap. The method is represented by the reaction
sequence:
CH2COR3 ICIHCOR3
O~l~R ~ H2N-Alk-N=B -~ ~C~
2 NH R2
Alk-N=B
VII
I, 7 l ~
7 Q
~17-
VII ~ ~ HO ~ C2-R3
il I
o Alk-N=B
By further chemical manipulations of various
functional groups in the compounds of formulas I, Ia and Ib
prepared by one or more of the above-described methods,
other compounds within the ambit of the invention can be
prepared. For example the compounds where R3 is amino-
phenyl are advantageously prepared from the correspond;ng
species where R3 is nitrophenyl by reduction of the latter.
The reduction can be carried out either catalytically
with hydrogen, for example over a platinum oxide catalyst
at ambient temperature and in an appropriate organic
solvent, such as a lower-alkanol, ethyl acetate or acetic
acid or mixtures thereof, at hydrogen pressures from around
30 to 60 p.s.i.g., or alternatively the reduction can
be carried out chemically, for example with iron in the
presence of hydrochloric acid in an appropriate organic
solvent, for example a lower-alkanol. The reaction is
carried out at temperatures from ambient to the boiling
point of the solvent used for the reaction.
The aminophenyl compounds thus prepared can then be
acylated or sulfonylated to prepare compounds where R3 is
lower-alkanoylaminophenyl, benzoylaminophenyl, trifluoro-
acetylaminophenyl or lower-alkylsulfonylaminophenyl by
reaction of an appropriate acid anhydride or acid halide
with the corresponding species where R3 is aminophenyl. It
is advantageous, although not essential, to carry out the
r . 7356
~25~30~(~
-18-
reaction in the presence of an acid acceptor, such as an
alkali metal carbonate, for example potassium carbonate, or
a tri-lower-alkylamlne, such as trimethyla~ine or tri-
ethylamine. The reaction is carried out in an inert
organic solvent at a temperature in the range from -5C. to
around B0C. Suitable solvents are acetic acid, MDC, EDC
or toluene.
Other simple chemical transformations which are
entirely conventional and well known to those skilled in
the art of chemistry and which can be used for effecting
chanyes in functional groups attached to the R3-carbonyl
group, (C=O)R3, involve cleavaye Oe aryl ether ~unctions, ~or
example with aqueous alkali or a pyridine hydrohalide salt
to produce thecorresponding phenoliccompound (R3ishydroxy-
phenyl); preparation of compounds where R3 is phenyl sub-
stituted by a variety of amine functions by reaction of the
corresponding halophenyl species with an appropriate
amine; catalytic debenzylation of benzyloxy-substituted
species to prepare the corresponding phenolic compound
(R3 is hydroxyphenyl); catalytic reduction of a nitrile
function to produce the corresponding aminomethyl-substi-
tuted species (R3 is aminomethylphenyl); saponification of
amide groups to produce the corresponding amino compounds;
acylation of hydroxy-substituted species to produce the
corresponding esters; acylation of amino-substituted
species to prepare the corresponding amides; oxidation of
sulfides to prepare either the corresponding S-oxides or
S,S-dioxides; reductive alkylation of amino-substituted
- 19 - ~L25;8~7~ 227~-3l9--
species to prepare the corresponding mono- or cli-lower-alkyl-
amino substituted species; reaction of amino-substituted
species with an alkali metal isocyanate to prepare the corres-
ponding carbamylamino-substituted species (~3 is carbamyl-
aminophenyl); reaction of an aminomethyl-subs-ti.tuted species
Wit11 a di-lower-alkylcyanocarbonimidodithioate and reaction oE
the resultiny product wi-th ammonia to prepare the corresponding
N-cyanoguanidinylmethyl-substituted species (R3 is cyanoguani-
dinylmethylphenyl); reduction o a cyano-substituted species
with sodium hypophosphite -to prepare a corresponding Eormyl-
substituted compound (R3 is Eormylphenyl); reaction of a formyl-
phenyl species or a R3-carbonyl species wit11 hydroxylamine to
prepare the corresponcling hydroxyiminomethylpllenyl-substituted
s~ecies (1~3 is hydroxyi~ omet1lylp1lenyl) or the 1~3-carbonyl
oximes (C=Z is C=NOII); reaction oE an aminophenyl species witll
a 2,5-di-lower-alkoxytetrahydrofuran to prepare a (l-pyrrolyl)-
phenyl-substi-tuted species (~3 is l-pyrrolylphenyl); oxidation
of the N=B function, for example by fermen-tative procedures,
or by oxidation with an organic peracid, such as perchloro-
benzoic acid, to prepare -the corresponding N-oxides; or reaction
of a l-aminoalkyl l~1-indole of Eormula III where ~2 is hydrogen
with hexamethylenephosp}1oramide followed by a lower-alkyl halide
to prepare the corresponding compounds of Eormula III where R2
is lower-alkyl.
The compounds of formulas I, Ia, Ib and III in Eree
base form are converted to the acid-addition salt form by
interaction of the base with an acid. In like manner, the
Eree base can be reyenerated from the acid-addi-tion salt form
in conventional manner, that is by treating the salts
o
~2513~
-20-
with cold, weak aqueous bases, for example alkali metal
carbonates and alkali metal bicarbonates. The bases thus
regenerated can be interacted with the same or a different
acid to give back the same or a different acid-addition
salt. Thus the novel bases and all of their acid-addition
salts are readily interconvertible.
It will thus be appreciated that formulas I, Ia, Ib
and III not only represent the structural configuration of
the bases of formulas I, Ia, Ib and III but are also
representative of the structural entities which are common
to all of the compound~ oE formulas I, Ia, Ib and III,
whether in the Eorm of the free base or in the form of the
acid-addition salts oE khe base. It has been found that,
by virtue of these common structural entities the bases of
formulas I, Ia and Ib, and certain of the bases of formula
III, and their acid-addition salts have inherent pharma-
cological activity of a type to be more fully described
hereinbelow. This inherent pharmacological activity can be
enjoyed in useful form for pharmaceutical purposes by
employing the free bases themselves or the acid-addition
salts formed from pharmaceutically acceptable acids, that
is acids whose anions are innocuous to the animal organism
in effective doses of the salts so that beneficial
properties inherent in the common structural entity
represented by the free bases are not vitiated by side
effects ascribable to the anions.
In utilizing th~s pharmacological activity of
the salts of the inventiont it is preferred, of course, to
use pharmaceutically acceptable salts. Although water
insolubility, high toxicity or lack of crystalline
-21-
character may make some particular salt species unsuitable
or less desirable for use as such in a given pharmaceutical
application, the water-insoluble or toxic salts can be con-
verted to the corresponding pharmaceutically acceptable
bases by decomposition of the salts with aqueous base as
explained above, or alternatively they can be converted to
any desired pharmaceutically acceptable acid-addition salt
by double decomposition reactions involving the anion, for
example by ion-exchange procedures.
Moreover, apart from their usefulness in pharma-
ceutical applications, the salts are useful as characteriz-
ing or identiEying derivatives of the free bases or in
isolation or purification procedures. Like all of the
acid-addition salts, such characterizing or purification
salt derivatives can, if desired, be used to regenerate the
pharmaceutically acceptable free bases by reaction of the
salts with aqueous base, or alternatively they can be con-
verted to a pharmaceutically acceptable acid-addition salt
by, or example, ion-exhange procedures.
The novel feature of the compounds of the invention,
then, resides in the concept of the bases and cationic
forms of the new 2-R2-3-R3-carbonyl-1-aminoalkyl-lH-
indoles of formulas I, Ia and Ib and the 2-R2-1-aminoalkyl-
lH-indoles of formula III and not in any particular acid
moiety or acid anion associated with the salt Eorms of the
compounds; rather, the acid moieties or anions which can be
associated with the salt forms are in themselves neither
novel nor critical and therefore can be any acid anion or
acid-like substance capable of salt formation with the
bases.
i) 7 j~u.~
~2~ 7~ -
-22-
Thus appropriate acid-addition salts are those
derived from such diverse acids as formic acid, acetic
acid, isobutyric acid, alpha-mercaptopropionic acidr malic
acid, Eumaric acid, succinic acid, succinamic acid, tar~
taric acid, citric acid, lactic acid, benzoic acid, 4-
methoxybenzoic acid, phthalic acid, anthranilic acid, 1-
naphthalenecarboxylic acid, cinnamic acid, cyclohexane-
carboxylic acid, mandelic acid, tropic acid, crotonic acid,
acetylenedicarboxylic acid, sorbic acid, 2-furancarboxylic
acid, cholic acid, pyrenecarboxylic acid, 2-pyridine-
carboxylic acid, 3-indoleacetic acid, quinic acid,
sul~amic acid, methanesulEonic acid, isethionic acid,
benzenesulfonic acid, p-toluenesulEonic acid, benzene-
sulfinic acid, butylarsonic acid, diethylphosphonic acid,
p-aminophenylarsinic acid, phenylstibnic acid, phenyl-
pho.sphinous acid, methylphosphinic acid~ phenylphosphinic
acid, hydrofluoric acid, hydrochloric acid, hydrobromic
acid, hydriodic acid, perchloric acid, nitric acid,
sulfuric acid, phosphoric acid, hydrocyanic acid, phospho-
tungstic acid, molybdic acid, phosphomolybdic acid, pyro-
phosphoric acid, arsenic acid, picric acid, picrolonic
acid, barbituric acid, boron trifluoride and the like.
The acid-addition salts are prepared by reacting
the free base and the acid in an organic solvent and
isolating the salt directly or by concentratio~ of the
solution.
In standard pharmacological test procedures, the
compounds of formulas I, Ia and Ib have been found to pos-
sess analgesic, anti-rheumatic and anti-inflammatory
activities and are thus useful as analgesic, anti-rheumatic
L . 73~A
~2~ 7~ -
-23-
and anti-inflammatory agents. Certain of the compounds of
ormula II have been found to possess anti-rheumatic
activity, and certain of the compounds of formula III have
been found to possess analgesic activity, thus indicating
S usefulness of those species as anti-rheumatic and analgesic
agents, respectively.
The test procedures used to determine the analgesic
activities of the compounds have been described in detail
in the prior art and are as follows: The acetylcholine-
induced abdominal constriction test, which is a primary
analgesic screening test designed to measure the ability of
a test agent to suppress acetylcholine-induced abdominal
constriction in mice, described by Collier et al., Brit.
J. Pharmacol. Chemotherap. 32, 295 (1968); a modification
of the anti-bradykinin test, which is also a primary
analgesic screening procedure, described by Berkowitz et
al., J. Pharmacol. Exptl. Therap. 177, 500-508 (1971),
Blane et al., J. Pharm. Pharmacol. 19, 367-373 (1967],
Botha et al., Eur. J. Pharmacol. 6, 312-321 (1969) and
Deffenu et al., J. Pharm. Pharmacol. 18, 135 (1966); and
the rat paw flexion test, described by Kuzuna et al., Chem.
Pharm. Bull., 23, 1184-1191 (1975), Winter et al., J.
Pharm. Exptl. Therap., 2 , 678-685 (1979) and Capetola et
al., J. Pharm. Exptl. Therap. 214, 16-23 ~1980).
Anti-rheumatic and anti-inflammato~y activities of
the compounds of the invention were determined using the
developing adjuvant arthritis assay in rats, the plasma
fibronectin assay in arthritic rats and the pleurisy macro-
phage assay in rats. The developing adjuvant arthritis as-
say was used in conjunction with the plasma fibronectin as-
say as a primary screening method in the evaluation of com-
~2.5~7CI
24 -
pounds for potential use as disease modifying ant;-
rheumatic drugs. The procedure used to induce arthritis in
rats is a modification of the methods pub:Lished by Dearson,
J~ Chron. Dis. 16, a63-874 (1973) and by Glenn et al.,
Amer~ J. Vet. Res. 1180-1193 (1965)o The adjuvant induced
arthritis bears many of the traits of rheumatoid arthritis.
It is a chronic, progressive, deforming arthritis of the
peripheral joints, with a primary mononuclear cell response
consisting of bone and joint space invasion by pannus. In
order to detect disease modifying anti-rheumatic drug
activity, drug treatment is started before the disease has
become irrevocably established. Since such drugs are not
deslgned to be administered prophylactically, drug treat-
ment of adjuvant arthritis is initiated at a time when the
disease is developing but is not yet irreversible. Animals
develop significant systemic arthritic disease which can be
measured by swelling of the non-injected rear paw (NIP) 15
to 20 days following an initial injection on day 1 of com-
plete Freund's adjuvant into the right hindfoot paw.
The important role played by fibronectin in
arthritis has been evidenced by clinical [Scott et al.,
Ann. Rheum. Dis. 40, 142 (1981)] as well as experimental
[Weissmann, J. Lab. Clin. Med. 100, 322 (1982)3 studies.
Plasma fibronectin measurements are made using the tech-
nique of rocket immuno-electrophoresis. Fibronectin
levels in the arthritic rat are significantly higher than
in normal animals. Nonsteroidal, anti-inflammatory drugs
have no influence on the enhanced fibronectin levels seen
in arthritic rats, while disease modifying anti-rheumatic
drugs cause a significant decrease in plasma fibronectin.
~ 7
-2S_
The pleurisy macrophage assay is designed to define
anti-arthritic drugs which inhibit macrophage accumulation
in the pleural cavity following injection of an inflam-
matory stimulus. Standard disease modifying anti-
rheumatic drugs are active in this assay while nonsteroidal
anti-inflammatory drugs are not. The activity of species
in the pleurisy macrophage model thus indicates disease
modifying anti-rheumatic drug activity. The macrophage is
the characteristic cell type in chronic inflammatory
responses in the rheumatoid synovium as well as other
sites. When activated, macrophages produce a large variety
of secretory products, including neutral proteases which
play a destructive role in arthritis lAckerman et al., J.
Pharmacol. Exp. Thera. 215, 588 (1980)]. The ln vivo
model of inflammatory cell accumulation in the rat pleural
cavity permits quantitation and differentiation oE the
accumulated cells. The cellular components are similar to
those seen in the inflamed synovium. It has been hypo-
thesized that drugs which are effectlve inhibitors of
pleurisy macrophage activity may also be effective in slow-
ing or reversing progression of arthritic disease (Ackerman
s~pra), and the procedure used is a modification of the
method published by Ackerman et al.
The compounds of formulas I, Ia, Ib, II and III of
the invention can be prepared for pharmaceutical use by
incorporating them in unit dosage form as tablets or
capsules for oral or parenteral administration either alone
or in combination with suitable adjuvants such as calcium
carbonate, starch, lactose, talc, magnesium stearate, gum
D N 35GA
-26-
acacia and the like. Still further, the compounds can be
formulated for oral or parenteral administration either in
aqueous solutions of the water soluble salts or in aqueous
alcohol, glycol or oil solutions or oil-water emulsions in
the same manner as conventional medicinal substances are
prepared.
The percentages of active component in such com-
positions may be var;ed so that a suitable dosage is
obtained. The dosage administered to a particular patient
is variable, depending upon the clinician's judgment using
as criteeia: the route of administration, the duration of
treatment, the size and physical condition of the patient,
the potency oE the active component and the patient's res-
ponse thereto~ An effective dosage amount of the active
component can thus only be determined by the clinician
after a consideration of all criteria and using his best
judgment on the patient's behalf.
The molecular structures of the compounds of the
invention were assigned on the basis of study of their
infrared/ ultraviolet and NMR spectra. The structures were
confirmed by the correspondence between calculated and
found values for elementary analyses for the elements.
The following examples will further illustrate
the invention without, however, limiting it thereto.
All melting points are uncorrected.
6 37~ ~
EXEMPLARY DISCLOSURE
Pre~aration of Intermediates
A. The Compounds of Formula II:
Preparation lA
To a solution of 0.05 mole of methyl magnesium
bromide in about 45 ml. of anhydrous diethyl ether at 0C.
under a nitrogen atmosphere was added, dropwise, a solution
containing 6.0 9. (0~04 mole) of 2,7-dimethylindole in 30
ml. of anhydrous ether. When addition was complete, the
10- reaction mixture was stirred at room temperature for one
hour r then cooled in an ice bath and treated dropwise with
a solution of 8.53 g. (0.05 mole~ of 4-methoxybenzoyl
chloride in 20 ml. of anhydrous ether. The mixture
was stirred at room temperature for approximately twelve
hours, then on a steam bath for two hours and then treated
with ice water. Excess ammonium chloride was added, and
the ether layer was separated, dried and evaporated to dry-
ness to give a solid which was collected by filtration and
washed thoroughly with water and ether to give 8.5 g. (76%)
of 2j7-dimethYl-3-(4-methoxy~ oyl~indole, m.p. 182-184C.
Preparations lB - lAU
Following a procedure similar to that described
above in Preparation lA, substituting for the 2,7-dimethyl-
indole and the 4-methoxybenzoyl chloride used therein an
appropriate 2-R~-R~-indole and an appropriate aroyl-
chloride (R3CO-Cl), the following species of formula II
listed in Table A were prepared. In some instances the
products, without further purification, were used directly
in the next step of the synthesis of the final products of
i` '. i3~A
7~ `-
-28-
formula I, and no melting points were taken. In a Eew
cases, the weight of the products was not obtained, and so
calculation of yields of products in those instances are
not possible. Here and elsewhere in the tables included
with this specification, the melting point of the product
(in C.) and the recrystallization solvent are given in
columns headed "m.p,/Solv. Il, and the yielcl, in percent, of
product is siven in columns headed "Yield".
:~.2~
~2~
Ta~Le A
PreprL R2 R3 R4 m.p./'Sclv. Yield
lB CH3 3 6 4 215-217/DMF--H20 85
lC CH3 2-furyl -- 98
lD CH3 4-CH3SC6H4
lE C~3 4-N2C6H4 - 23
lE' CH3 4-CH3OC6H4 5-F 199-202/i-PrOH
lG C H3 3 6 4 7-F204-?05/H 2 42
lH CH3 4-Cl~3Oc6~47-CH30 68
l-I CH3 4CH30C6H4~/7-F(a) 55
lJ CH3 4 FC6 4 199-201~EtOH38
lK CH3 3'4-~CH2~6E~3 210-213/i-PrOH 60
lL CH3 3~enzolb]thienyl - 181-183 64
lM C~33 2~enzo[b]fury1 - 218-220/i-PrOH 62
lN CH3 2-CH3OC6H4 - 203-206/i-PrOH 75
1-0 CH3 3-F-4-CH30C6113 160-165/EtOH 39
]P CH3 2-naphthyl - 208-213/i-PrOH 57
lQ H 4 CH3OC6H45-CH3 189-192~EtO31 42
lR CH3 3-FC6H4 - 64
lS CH3 2 F 6 4 216-218/i-PrOH 44
lT CH3 4-CNC6H4 - 211-213/EtOAc 7
lU CH3 C6i35 4C~3 176-179/EtOAc 65
lV C E33 4 2 5 6 4 199-201~EtOAc 70
lW CH3 3-N02C6H~a ~218-221~DME'-H20 20
lX CH3 4 3 6 4 207-209/EtOH60
lY CH3 3-CH30C6H~ - 163-164/EtOAc 63
lZ H 4 3 6 4 80~b)
lAA C6H5 4-CH30C6H4 - 25
lAB H C6H5 5-CH30 46
lAC CH3 4-CH3OC6H46-CE330 53
lAD CH3 4 NO2 6 4 6-CH3O 73
lAE C H 3 C 6 H 5 -185-186/M eO H 64
lAF H C6H5 ~ 241-242/MeOH38
lAG CH3 4-ClC6H4 - 183-185/MeOH34
lAH CH3 4-CH3OC6H4 6-C1 58
lAI CH3 4-CH~,4 6-C6H5CH2O 51
lAJ CH3 2,3 CH2 6 3 239.5-240/CH3CN 98
lAK CH3 2 6 5 6 4 238-240/MeOH 39
lAL CH3 4 6H5C6H~ 225-228 56
~ . ! i, ' ~ ` :
3~ 7~ ~
3o-
Table A con~d.
Prepn. R2 R3 R4 m.p./S~v. Yield
__ _ __
lAM CH3 l~aphthyl - 223-224/i-PrOH 69
lA N C H 3 2,3-(C H 3 (~) 2C 6 H 3 185-187 B7
lAO CH3 3,~(CH30~2C6H3 182-184 85
lAP C H (C H 3) 2 4-C H 3 O C 6 H 4 ether
lAQ C~(cH3)2 4-CH3OC6H4 ~F 173-175 11
lAR CH3 2-FC6H4 5-F 247-249/i-PrOH 10
lAS C H3 4-CH30-1-naphthyl - 286-289/i-PrOH 24
lAT CH3 4-C6H5C6H4 5-F 234-235.5/EtOH 36
lAU CH3 4-CH3OC6H4 - 200-203 97
(a~ Product cons~sted of a m~xture of the ~lluoro and the 7-fluoro isomers.
b) Two mc~ar equivalents of the Grignard reagent used, thus res~ting in
acyla~ion at both the 1- and 3-po6itions of indcde denvative. The de3red
product was obtained by ileating a mixture of the crude product in methar~L
and sodium hydroxide.
n._ 735~A
5~37~
Preparation lAV
A mixture of 50 g. ~0.03 mole3 of phenylmercapto-
acetone and 76.8 g. (0.3 mole) of 3 benzyloxyph~nylhydra-
zine in 750 ml. of ethanol was heated on a steam bath for
six hours and then stirred at room temperature or about
twelve hours The solid which separated was collected,
washed with water and the filtrate set aside. The solid
was dissolved in methylene dichloride, the organic solution
was washed with water, then with dilute hydrochloric acid,
- dried over magnesium sulfate, filtered and taken to dryness
to yield a first crop of crude product which was stirred
with ether for about Eorty-eight hours and then filtered
and dried to give 56 g. Oe product. The original filtrate,
previously set aside, was mixed with methylene dichloride,
and the organic layer was washed with water, then with
d~lute hydrochloric acid, dried over magnesium sulfate,
filtered and concentrated to dryness to give 40 g. of
additional product which was recrystallized from diethyl
ether/methylene dichloride to give 29.7 g. of product (com-
bined yield 71.7 g., 69%) of 2-methyl-3-phenylmercapto-6-
benzyloxYindole, m.p. 146-14~C.
A mixture oE 25 9. (0.072 mole3 of the latter with
50 teaspoons of a Raney nickel/ethanol suspension in 1
liter of ethanol was heated under reflux for three hours,
stirred at ambient temperature for about twelve hours, then
refluxed for an additional three hours and the catalyst
7~
-32-
removed by filtration. The filtrate was taken to dryn~ss
in vacuo to give an oil which was passed through a pad of
Florisil and eluted with ethyl acetate. Evaporation of the
solution to dryness afforded 5.2 g. ~26%) of 6-hydrox~-
2-methylindole.
A mixture of 5 9. (0.034 mole) of the latter,
S 9 ml (0.051 mole) of benzyl chloride and 13.8 9. (0.1
mole) of potassium carbonate in 200 ml of DMF was stirred
at room temperature for two hours, then heated on a steam
bath for two hours and the mixture poured into ice/water.
The solid which separated was collected, dissolved in ethyl
acetate, and the organic solution was washed with water,
then with brine, dried over magnesium sulfate, filtered and
taken to dryness to give 2.5 g. of 6-benzyloxy-2-methyl-
indole, m.p 90-93C., used as the starting material for
the preparation of the compound of Preparation lAI in Table
1 above.
Preparation 2
To a solution of 20 g. ~0.071 mole) of 2-methyl-
3-(4-methylmercaptobenzoyl)indole (Preparation lD) in 400
ml of chloroform was added, dropwise with stirring, a
solution of 16.7 g.(00081 mole) of 3-chloroperbenzoic acid
(80~) in 170 ml. of chloroform while cooling the mixture
in an ice/methanol bath When addition was complete, the
solution was stirred at room temperature for approximately
twelve hours and then washed three times with saturated
sodium bicarbonate solution and dried over magnesium
sulfate. The mixture was filtered, the filtrate was
~25807~ 1. 7356A
concentrated to near dryness, and the solid which separated
was oollected and recrystallized from ethyl acetate to give
14.5 g. ~69%) of 2-methyl-3-~4-methylsulEinylbenzoyl)-
indole.
-
Preparation 3
- 5 2-Methyl-3-(4-nitrobenzoyl)indole ~Preparation lE)
(11.2 g., 0.04 mole) dissolved in a solution oE 100 ml. of
glacial acetic acid and 200 ml. of ethyl acetate was
reduced with hydrogen over 0.6 g. of platinum oxide
catalyst in a Parr shaker, and when reduction was complete,
in about two and a halE hours, the catalyst was rernoved by
filtration and the solvent taken off in vacuo to leave 11.4
g. oE crude product, which was recrystallized from ethanol
to give ~.5 g. (45%) of 2-methyl-3-(4-aminobenzoyl)-
indole, m.p. 220-223 C.
B. The Compounds of_Formula III
(a) By Alkylation of the Compounds of Formula IV
Preparation 4A
To a stirred suspension of 229.5 9. (1.22 moles) of
N-(2-chloroethyl)morpholine hydrochloride in 300 ml. of
DMSO at ambient temperature was added 200 g. (3.03 moles)
of 85% potassium hydroxide pellets, and the suspension was
stirred for five minutes and then treated dropwise at
ambient temperature with a solution of 133.7 9. (1.0 mole)
of 2~methylindole in 140 ml. of DMSO. The temperature of
the reaction mixture"'graduaLly rose during the addition of
the 2-methylindole as well as on stirring after adclition
L . 7:35bA
~5~30~(3
-34-
was complete. When the temperature reached 78~C.; the mix-
ture was cooled in a water bath until the temperature sub-
sided to 75C., and the mixture was stirr~ed for a total of
three and a half hours while the temperature subsided to
ambient. The mixture was then diluted with 1 liter of
water and extracted with toluene. The extracts were washed
with water, dried over magnesium sulfate and taken to dry-
ness ln vacuo, and the residual dark oil was crystallized
from heptane to give 224 9. (92%) of 2-met~1-1-[2-(4-
morpholinyl~ethyl]-lH-indole, m.p. 63-65C.
Preparation 4B
Following a procedure similar to that described
above in Preparation 4A, 20.0g. (0.134 mole) of 5-fluoro-2-
methylindole were reacted with 2~.1 g. tO.147 mole) oÇ 4-
~3-chloropropyl)morpholine in 46 ml. of dry DMF in the
presence of 8.0 g. (0.201 mole) of a 60~ mineral oil dis-
persion of sodium hydride. The product was isolated in
the form of its maleate salt to give 30.0 9. (81%) of 5-
fluoro-2-methyl-1-E3-(4-morpholinyl~propyl]-lH-_ dole
maleate, m.p. 165-167C.
Preparation 4C
Following a procedure similar to that described in
Preparation 4A, 50 g. (0.43 mole) of indole were reacted
with 159 g. (0.85 mole) of 4-(2-chloroethyl)morpholine in
850 ml. of dry DMF in the presence of 209 9. (0.50 mole) of
a 60~ mineral oil dispersion of sodium hydride. The
product was isolated in the form of the free base to give
45.6 g. (46%) of 1-[2 (4-morpholinyl)ethyl~ -indole.
, . 7356A
_. ~.
-35-
Preparation 4D
.
To a .stirred suspension of 322 g. (0.81 mole)
of a 60~ mineral oil dispersion of sodium hydride in
250 ml. of dry DMF was added dropwise a solution of 100
9. (0.67 mole) of 5-fluoro-2-methylindole in 300 ml.
of dry DMF. The mixture was stirred at ambient temperature
for thirty minutes and then treated dropwise with
cooling with a solution of 121.5 9. (0.67 mole) of ethyl ~-
bromopropionate. Workup of the reaction mixture, after
quenching with water and extraction of the product with ethyl
acetate, afforded ethyl a -(5-Eluoro-2-methyl-1-indolyl)-
ionate.
The latter was reduced with 525 ml. of a lM solution
of diisobutyl aluminum in 1150 ml. of toluene to yive 130
9. (94%) of 5-fluoro-2-meth~=1-(1-methyl-2-hydroxyethyl)-
lH-indole.
The latter, on reaction with 144 9. (0.76 mole)
of p-toluenesulfonyl chloride in 350 ml. of pyridine
using the procedure described in Preparation 7A afforded
65 9~ (20%) of 5-fluoro-2-methyl-1-[1-methyl-2-(p-toluene-
sulEo~yloxy)ethyl]-lH-indole~ m.p. 136~140C.
(b) Via the Amides of Formula V
_
Preparation 5A
Following a procedure similar to that described in
P~eparation 4 above, 32.8 9. (0.25 mole) of 2 methylindole
in 160 ml o~ dry DMF was reacted with 13.4 g. (0.28 mole)
of a 50~ mineral oil dispersion of sodium hydride in 200
ml. of dry DMF, and the resulting sodium salt was then
reacted with 62 g. (0.28 mole) of 4~ bromopropionyl)-
morpholine in 160 ml. of DMF to give 55.3 g. tS9~) of 4-[~-
12-methyl-lH-i ol-l~yl)~o~ionyl]morpholine.
7~ _
-36-
The latter (130 g., 0.48 mole), dissolved in 900
ml. of THF, was added to 80 ml. (0.80 mole) of a solution of
boron methyl sulfide complex in THF under nitrogen while
cooling in an ice bath. When addition was complete, the
mixture was stirred for eighteen hours at room temperature,
heated under reflux for four hours, quenched by addition of
about 1 liter of methanol, boiled for about fifteen min-
utes, concentrated essentially to dryness and then diluted
with aqueous 6N hydrochloric acid. The mixture was ex-
tracted with methylene dichloride, and the raffinate was
basified with 35% sodium hydroxide and extracted with ethyl
acetate. The combined organic extracts were washed with
brine, dried and concentrated to dryness to give 42.6 g.
(34~ of 2-methyl 1-[1-methyl-2-(4-morpholi~yl)ethyl]-lH-
indole as an oil. A portion of the latter was reacted with
methanesulfonic acid to give the monomethanesulfonate as
the 4:1 hydrate, m.p. 154-157C.
Preparation 5B
Following a procedure similar to that described
in Preparation 5A above, 29.29 9. (0.25 mole) oE indole in
200 ml. of dry DMF was reacted with 13.4 g. (0.28 mole) of a
50~ mineral oil dispersion of sodium hydride in 200 ml. of
dry DMF and the resulting sodium salt reacted with 62.0 g.
(0.28 mole) of 4-(a-bromopropionyl)morpholine in 200 ml. of
dry DMF and the product recrystallized from isopropanol to
give 13.7 g. (21%) of 4-[~-(lH-indol-l-yl)propionyl~-
morpholine, m.p. 92-94C. The latter (20 g., 0.07B mole)
in 300 ml. of diethyl ether was reduced with 3.12 g.
10.078) mole of lithium aluminum hydride in 100 ml. of di-
ethyl ether to give 17 g. (90%) of 1-~1-methyl-2- ~-m~E~
linyl)ethyl]-lH-indole, m.p. 35-37C
-37-
Preparation 5C
Following a procedure similar to that described in
Preparation 5B, 83 g. (0.63 mole) of 2-methylindole was
reacted with 30 g. (0.75 mole) of a 60~ mineral oil dis-
persion of sodium hydride, and the resultirlg sodium salt was
reacted with a molar equivalent amount of 4-(~-bromo-
butyryl)morpholine in 100 ml. of DMF. The crude procluct
thus obtained was reduced with 25 g. (0.66 mole) of lithium
aluminum hydride in 500 ml. of THF. The product was
isolated in the form of the hydrochloride to give 53.4 g.
(27~) of 2-methyl-1-[l~ethyl-2-(4-morpholirlyl)ethyl]-lH-
indole hydrochloride, m.p. 159-162C. ~from ethyl acetate-
ether).
Preparation 6
To a solution of 23 g. (0.1 mole) of 1-[2-(4-morpho-
linyl)ethyl]-lH-indole ~Preparation 4C) in 120 ml. of THF
was added 60 ml. of 2.1M butyl lithium in hexane while
maintaining the temperature at 0C. The mixture was
allowed to warm up to room temperature and was then treated
with 18 ml. of hexamethylphosphoramide followed by 10 ml.
of ethyl iodide while maintaininy the temperature at 0C.
The mixture was then quenched with ice, extracted with
ether, and the combined organic extracts were washed first
with water, then with brine, dried over magnesium sulEate,
taken to dryness and chromatographed on silica gel, eluting
with 40:50 ethyl acetate:hexane. Four fractions were
obtained which, on evaporation to dryness, afforded 4.0 g.
of a yellow oil from the first fraction and 9.6 g., 3.6 g.
and 4.2 g. of solid material in the next three fractions.
These ractions were recrystallized rom hexane to
give 8.3 g. (32~) of 2-ethyl-1-[2-(4-mo~pholinyl~ethyl]-lH-
indole, m.p. 59-60.SC.
D.i~. 7~~6n
~2~
-38- 22749-319G
C. The Co~pounds of Formula VI
Prepar~tion 7A
To a suspension of 50 9. (Ool9 mole) of 2-methyl-3-
(4-methoxybenzoyl)indole [Pxeparation l~U) in 400 ml. of
THF was added, over a one and a half hour period t 74.25 ml.
(0.19 mole) of a 2.6M solution of n-butyl lithium in
hexane. The reaction mixture was stirred for one hour at
0C., at room temperature for forty-five minutes, recooled
to 0C. and treated dropwise, over a thirty minute period,
with a solution of 93.7 ml. (0.19 mole) of a 2.06 M
solution of ethylene oxide in THF. The reaction mixture
was gradually allowed to warm to room temperature and then
treated with 200 ml. of a saturated ammonium chloride
solution. The solvent was removed in vacuo, the residual
solid was filtered, washed with water and extracted with
boiling ether, and the ether extracts were taken to dryness
to give 23 g. (39%) of 2-methyl-3-(4-methoxybenzoyl)-1-(2-
hydroxye hyl)-lH-indole, m.p. 75-78C.
A solution of 10 g. (0.032 mole) of the latter
and 6.48 9. (0.034 mole) of p-toluenesulfonyl chloride in
100 ml. of pyridine was stirred at room temperature for
about twelve hours and the reaction mixture diluted with
ethyl acetate and washed with water. The organic layer was
separated, dried over magnesium sulfate, filtered and con~
centrated to dryness to give a brown gum. The latter was
dissolved in methylene dichloride and the solution chroma-
tographed on a short column of Florisil~ to give 7.8 9.
(52%) of 2-methyl-3-~4-methoxyben2Oyl)-1-(2-p toluene-
sulonyloxyethyl)-lH~indole, m.p. 62-65C.
*Trademark
D.N. 7' A
~L25i~ 70
-39-
Preparation 7B
Following a proceduxe similar to that described
in Preparation 7A above, 9.75 g. t0.0375 mole) of 2-methyl-
3-~4-cyanobenzoyl)indole (Preparation lT) in 125 ml. of TH~
was treated with 16.65 ml. (0.04 mole) of a 2.4M solution
of n~butyl lithium in hexane followed by 11.4 ml. of a
3.SM solution oE ethylene oxîde in THF to give 2-methyl-3
~4-cyanobenzoyl)-1-~2-hydroxyethyl)-lH-indole. Reaction
of 30.4 9. (0.1 mole) of the latter with 21.0 g. (0.11
mole) of p-toluenesulfonyl chloride in 50 ml. of methylene
dichloride in the presence oE 50 ml. oE 35~ sodium
hydroxide and 0.91 g. (0.004 mole) of benzyl trimethyl-
ammonium chloride aEforded 38.3 9. (84~) of 2-methyl-3-(4-
cyanobenzo~L-1-(2-~-toluenesulfonyloxyethyl)-lH-indole,
m.p. 165-167C.
Preparation 7C
Following a procedure similar to that described
in Preparation 7A above, 20 g. (0.1 mole) of 2-methyl-
3-(4-ethylbenzoyl)indole (Preparation lV) in 200 ml. of THF
was treated with 51 ml. (0.11 mole) o a 2.15 M solution of
n-butyl lithium in hexane followed by 6.16 g. (0.13 mole)
of ethylene oxide to give 18 g. (73%) of 2-meth~1-3-(4-
ethy~benzoyl)-1-(2-hydroxyethyl)-lH-indole. Reaction of
the latter (0.058 mole) with 14.32 9. (0.075 mole) of p-
toluenesulfonyl chloride in 400 ml. of methylene dichloride
in the presence of 50 ml. of 35% sodium hydroxide and 1.6
9. (0.0076 mole) of benzyl trimethylammohium chloride
afforded 27 g. (95~) of 2-methyl-3-(4-ethylbenæoyl)~1-(2-
p-tolueneSulfonyloxyethyl)_-lH-indole as a red oil.
~L ~5~7~ D . N . 7 _~, .' A
.
-40-
Preparation 7D
A solution of 5.0 9. (0.068 mole) of 2-methyl--
5-Eluoro-3-(4-methoxybenzoyl)indole (Preparation lF) in
100 ml. of dry DMF was cooled in an ice bath at 0C and then
treated with 18.17 9. (0.09 mole) of 1,3-dibromopropane.
The solution was stirred for a few ~inutes at 0C, then
treated portionwise with 1.08 9. t0.027 mole) of a 60~
mineral oil dispersion of sodium hydride, stirred for about
fifteen minutes in an ice bath, then for an additional
twelve hours at ambient temperature, treated with a small
amount of water and taken to dryness in vacuo. The residue
was partitioned between water and methylene dichloride, the
organic layer was separated, washed first with water, then
with brine and then dried and taken to dryness. Crystal-
lization of the residue from ethanol aEforded 4 g. ~55~) of
1 (3 bromoproPyll-5-fluoro-2-methyl-3-(4-meth~y~enzoyl)
lH-indole, m~p. 133-135C.
Preparation 7E
Following a procedure similar to that des~ribed
in Preparation 7D above, 60 9. (0.23 mole) of 2-methyl-3-
(4-methoxybenzoyl)indole (Preparation lAU) was reacted
with 244.1 9. (1.13 mole) of 1,4-dibromobutane in 200 ml
of DMF in the presence of 13.8 9. (0.34 mole) of a 60~
mineral oil dispersion of sodium hydride, and ~he product
recrystallized from ethyl acetate/hexane to give 5.0 9. of
1-(4-bromob~y~lL~_methyl-3-~4-methoxybenzoyl)-lH-indole,
m.p. 83-86C.
D. 1`1. , o~
,A~ 7~
-41- 22749-319G
Preparation 7F
Following a procedure similar to that described in
P~eparation 7D above, 35 g. ~0.122 mole) of 2-methyl-3-~1-
naphthylcarbonyl)indole (Preparation lAM) was reacted with
124 g. (0.614 mole) of 1,3-dibromopropane in 700 ml of DMF
in the presence of 7.5 9. (0.188 mole3 of a 60% mineral oil
dispersion of sodium hydride, and the product purified by
chromatography on Kieselgel 60 in 50% ethyl acetate/hexane.
There was thus obtained 18.38 9. (37%) oE 1-~3-bromo-
propyl)-2-methyl-3-(1-naphthylcarbonyl~-lH-indole, m.p.
115-116~C.
Preparation 7G
Following a procedure similar to that described in
Preparation 7D above, 73.86 g. tO.3 mole) of 2-methyl-3-(4-
methoxybenzoyl)indole (Preparation lAU) was reacted with
302.33 g. ~1.5 moles) of 1,3-dibromopropane in 250 ml. of
DMF in the presence of 17.97 g. (0.45 mole) of a 60~
mineral oil dispersion of sodium hydride. There was thus
obtained l-(3-bromopropyl)-2-methyl-3-(4-methoxy~_nzoyl)-
lH-indole.
Preparation 7H
Following a procedure similar to that described in
Preparation 7D above, 15.0 9. (0.053 mole) of 5-fluoro-2-
methyl-3-(4-methoxybenzoyl)indole (Preparation lF) was
reacted with 9.18 g. (0.058 mole) of 1-bromo-3-chloro-
propane in 232 ml. of DMF in the presence of 3.2 9. (0.0795
mole) of a 60% mineral oil dispersion of sodium hydride.
There was thus obtained 15.3 g. (80~) of 1- L3-chloro-
pr~pyl)-5-fluoro-2-methyl-3-(4-methoxybenzoyl)-lH-indole.
*Trademark
D.i~
~LZ51~7~ _
-42-
Preparation 7I
.
Following a procedure similar to that described in
Preparation 7A above, 24.8 9. (0.087 mole) of 2-methyl-3-
(l-naphthylcarbonyl)indole ~Preparation lAM) in 300 ml. of
THF was treated with 35 ml. (0.09 mole) of a 2.6M solution
of n-butyl lithium in hexane followed by 56 ml. of a 2.6M
solution of ethylene o~ide in THF to give 21.3 9. (74~) of
2-methyl-3-~1-naphthylcarbonyl)~ (2-hydrox~ethyl)-lH-indole.
Reaction of the latter (0.~65 mole) with 18.5 9. (0.097
mole) of p-toluenesulfonyl chloride in 400 ml. of methylene
dichloride in the presence of 340 ml. of 35% sodium
hydroxide and 0.6 9. (0.0026) mole of benzyl trimethyl-
ammonium chloride afEorded 20.1 9. (64~) of 2-methyl-3-(1-
naphthylcarbonyl)-l-~2-p-toluenesulfon~loxyethyl~-lH-indole
as a viscous oil.
Preparation B
A solution of 42 9. ~0.116 mole) of 5-fluoro-2-
methyl-l-ll-methyl-2-(p-toluenesulfonyloxy)ethyl]-lH-indole
(Preparation 4D) and 50 ml. of morpholine in 400 ml. of DMF
was heated on a steam bath for seventy-two hours, poured
into water and the mixture extracted with ethyl acetate.
The combined organic extracts were dried and taken ~o dry-
ness to give 20 9. of crude product which was purified by
HPLC, eluting the product with 2:1 hexane:ethyl acetate.
There was thus obtained 10.4 g. (32%) of 5-fluoro-2-methyl-
1-[1-methyl-2-~4-morpholin~l)ethyl]-1~-indole as the
first, third and fourth through the seventh fractions.
The second frackion, on conversion to the hydro-
chloride salt and recrystallization from methanol-ether,
~25t3~!7~
-~3-
afforded 1.0 g. of 5-fluoro-2-methyl-1-[1 _ thyl-2-(dl-
methylamlno)ethylJ-lH-indole hydrochloride, m.p. 208.5-
211.5C, produced by amination of the tosylate by the DMF used
as a solvent.
It is contemplated that, by replacing the moepholine
in the above-described procedure with dimethylamine, the
dimethylamino species can be obtained as the major product.
Preparation_9A
Following a procedure similar to that described in
Preparation 5~ above, 24.0 g. (0.071 mole) of 5-fluoro-2-
methyl-3-(4-methoxybenzoyl)indole (Preparation lF) in 200
ml of dry DMF was reacted with 35.2 9. (0.35 mole) of
epichlorohydrin in the presence of 3.1 g. (0.078 mole) of a
60% mineral oil dispersion of sodium hydride in 100 ml. of
DMF. The product was recrystallized from ethyl acetate-
hexane to give 10.6 g. (44%) of 5-Eluoeo-2-methyl-3-(~-
methoxybenzoyl~ [1-(2,3-epoxy)propyl]-lH-indole as a
yellow solid.
Preparation 9B
Following a procedure similar to that described in
Preparation 9A above, 100 9. ~0.377 mole) of 2-methyl-3-(4-
methoxybenzoyl~indole (Preparation lAU) in 1500 ml. of DMF
was reacted with 174.6 g. (1.89 moles) of epichlorohydrin
in the presence of 19.92 g. ~0.42 mole) of a 50~ mineral
oil dispersion of sodium hydride in 500 ml. of DMF. There
was thus obtained 2-methyl-3~14-methoxybenzoylL~1-[1-(2,3-
epoxy)pro~yl]-lH-indole.
D,i~, 7356A
~25!3~
-44
Preparatlon 9C
Following a procedure similar to that described in
Preparation 9A above, 28.7 9. 10.1 mole) of 2-methyl-3~
naphthylcarbonyl)indole (Preparation lAM) in 165 ml. of
DMSO was reacted with 27.39 9. (0.2 mole) of epibromohydrin
in the presence of 6.6 g. (0.1 mole) of powdered potassium
hydroxide and the product purified by chromatography on
silica gel, eluting with ethyl acetate-hexane. There was
thus obtained 32.3 g. (95~) of 2-methyl-3-(1-naphthyl-
carbony~)-1-[1-~2,3-epoxy)propyl]-lH-indoleO
i . /3~
~2S~
,
-~5-
Preparation of the Final Products oE Formula I
A. From_the Compounds of Formula II
Example lA
Following a procedure similar to that described
in Preparati~n 4 above, 25 9. (0.10 mole) of 3-(4-methoxy-
benzoyl)indole IPreparation lZ) in 100 ml. o 3MF was
reacted with 5.76 g. (0.12 mole) of a 50% dispersion of
sodium hydride in mineral oil in 120 ml. of DMF, and the
resulting sodium salt was reacted with 0 .14 mole of 4-(2-
chloroethyl)morpholine (freed from 26.06 9. of the corres-
ponding hydrochloride) in 120 ml. of DMF to give 42 9. of
the cxude product as an oil which, on trituration with
ethyl acetate/diethyl ether/hexane, gave a yellow crystal-
line solid which was converted to the methanesulfonate salt
to afford 9.5 g. (20%3 of 3-~4-methoxybenzoyl)-1=[2-(4-
mox~holinyl)ethyll-lH-indole methanesulfonate monohydrate,
m.p. 110-112~C.
Examples lB-lC~
Following a procedure similar to that described
in Example lA above, the following species of formula I
in Table 1 were prepared by reaction of a 2-R2-3-R3-carbonyl-
lH-indole of formula II with an appropriate halo alkyl-
amine or tosyloxyalkylamine. The acid-acceptor and
reaction solvent used in the reactions are given in the
column headed "Cat./Solv.". Here and elsewhere in the
tables, the form in which the product was isolated, either
as the fxee base or as an acid-addition salt, is given in
i . 7~0~
~5~3~317~
-46-
columns headed "sase/salt"~ and the abbreviations
"MorphO", "Pip." and "Pyr." in the co;Lumns headed N=B
represent the 4-morpholinyl, l-piperidinyl and l-pyLro-
lidinyl groups, respectively. In Table 1, unless noted
otherwise, an appropriate chloroalkylamine was used as the
alkylating agent. Here and elsewhere in the specification
and the claims, the alkylene groups, Alk, are depicted as
they would appear with the l-indolyl moiety attached to the
carbon atom at the left.end of the alkylene chain and with
the amine group, N=B, attached to the carbon at the right
end of the chain.
o
--47--
7 ~ n ~ u ~ 115 m ~ u u u Y u
s ~ 1 ~ s s 3
~ K Y y y ' = = ~ = U~ U~ U~, U~ ~ R
Z I S S :E: S ~ S ~ S ~ S ~
~ I ~ a u ~ u ~ u e s~ u u ~ u ~ 5~ ~
u u ~ 0 0 0 0 0" ~
tlN¦ CJ S U U U ~ U C U a u 3 ' u u u ~ 1 ~ U
U Q ~ E Z ~ D
r,~ .
1) ~. 73~A
~25~3 [37~
--48--
o r~ o o~ o
v v
u o ~ v O v
d. 0~ T~ ~æ ~ 5
n ~ S S ~
a
u uuuuUUU;UU~U~UUUt-)
uUUUUUUUUUUUUUUyUU YU
o o o o
o~l l x l l l ~ l l l l l l l I x ~
y~ ~ U~ W~ O U~ ~.,U~ U~ W~
u u ~ u v u u u u u u o u u ~ 3
1 U Q ~ h. t~ z O
. i ~" i
D.~. 73';!~A
--49--
h a S ~ ~ S ~ ~ ~ h ~
1 W ~ u o ~ ~
~ I ~ = S T S S S S ~ S
~¦ N ~ ~ N U U~ U N W U ~ U U U ?`l ?~
O O N i~ e
tlIIIXIItIIIII I ~,~, ~
O t ~ t ~0 ~ ~
~W~ ~v~,,~,,,,,,uu ,,",~o ~
U U U 1 U U :s~ V U t~ U U t~ U U U U
~a ¦ rt ~ ¢ d ~ at
P1 , .
- D._~ 73~A
-50-
d ~ U~ N~ ~ I O O
3 3 3 3~ ~ ~ d d 3 u u 3 tc
~ ~ s ~ 2 s ~ ~" Q ~t4 tq t4 tq tq ~4
' ~ Q ~ U~z ;~
m I ~ U ~ , u ~
U 2 ~ U U U r~ U ~ s
U 2 W U U U r~ U r~
U ~ U U U U U U W~ 3~ ~: U U U V U U U U
U ~ U U U ,~
~ ¦5 Y ~ u Y y y y Y ~; y ~ Y Y Y N X y ~ ~ y y ry
~IU-~U~Ut~UUUUVUUUUUUU~UU~
~L ¦ N ~ p O ~ 5 ~ = ' d u d ~, o u ~
_ D.~. 73~;~F\
~25~
.
--51--
g ~ J c~ o
~ ~ '
o ~
m ~
.: ~ r,. I4 ~, P4 ~, ~, p ~4
e ~a ~a ~a ~? a
U ZZZZZZZ:4
Z ~
?~
Y U y ~ y ~ U y
X
U
~ X ~ ô o ~ ~ X
u ~O ~ ~ ~ tJ U
a~YYYxw~
~ t~ Z ~
~` ~ ~ ~ ~ ~r
r~ ~
3~ X
U ~ ~ X
eD' ,, :c ~ z o C4 cl c~
~: U tJ ~J ~ V C
W ~
1. 7~'jbA
- ~5~
-52-
8. From the Compounds of Formula III
Example 2A
To a stirred, refluxing solution of 13.2 g. (0.054
mole) of l-[l-methyl-2-(4-morpholinyl)ethyl]-lH-indole
tPreparaticn 5B) in 150 ml. of ethylene dichloride was
added, over a period of about one hour, a mixture of 17.35
9. (0 13 mole) of aluminum chloride and lO.OB 9. (00065
mole) of 4-methylbenzoyl chloride in 200 ml. of ethylene
dichloride. When addition was complete, the mixture was
heated under reflux under a nitrogen atmosphere Eor three
and a half hours and then poured, with stirring, into 1
liter of ice and water containing 300 ml. of 5N sodium
hydroxide. The mixture was trans~erred to a separatory
funnel, the organic layer was separated, and the aqueous
; 15 layer was washed with an additional 300 ml. of ethylene
dichloride. The combined organic extracts were then washed
with brine, filtered, dried over magnesium sulfate,
Eiltered again and evaporated to dryness to give a viscous
oil (22.55 9~) which solidified on cooling. The latter was
~0 recrystallized, after charcoaling, from isopropanol to
give 15.78 9. ~81%) o~ 3-(4-methylbenzoyl)~ methyl-2-
(4-morpholinyl)ethyl] lH-ind_le, m.p. 116.5-118C.
D. ,~
o~
Bxamples 2B-2BI
Following a procedure similar to that described
in Example 2A above, the following species of formula I
in Table 2 below were prepared by reaction of a 2-R2-
l-aminoalkyl-lH-indole of formula III with an appropriate
acid chloride (R3CO Cl) in the presence of aluminum chloride.
The solvent used to carry out the reaction, methylene
dichloride (MDC) or ~thylene dichloride (EDC), is given
in the column headed "Solv."
D.~ 735~;A
~2~
--54--
I
~D
oooo~o~ o~ oo~oo~o
~ Jd ;~ r ~ r
E~i r~ r1 ;~ r~
i~ 0~ ~
~:J lii
~' ¦ U ~J a U U U U U U U U U U U U U U U U U U U U U U U ~'
W W Pl ~1 W W W W t~ 1 2 W :1: S S ~ W
z S S ~ ~ E S S 2
rJNNNN~NNN N
VUUUU~UUU U~NNNNNNrJN r~ NNNNNN r~
~rr~U~ ~N~N~ ~I~E
U U U V V y, V y~ W ~ V ~J U U U U r
W~ ;~
.rlIIIIII IrU~ IIIIIIIII IIIII~II
u U O ~ ~ y r~ X u = y ~ X ~ X ~ u
N ~ ~X~ WW~W~
n u u ~ u u :~: u ~ u u ~ u t~ U u ~ u ~ u u
~U~ ~ ~NN01~ ~ æ x ~ ~ ~
~N~N ~N~ NNN~ NN~ ~ NNN~N
r~
D,r~. 7356A
-- ~25~ 7~
--55--
~1
~ O O O ~ O ~ 3: U
~1 ~
¦ a Q a Q a Q Q ~ g t~ a a Q tQ a a Q Q
S S :~: S :~: S S :C W W S :1: W W W ~E W
1 N
N ~ ~ ~ ~ 1'~ ,, t~ t~ ~`1 N 1`1 ~ ~ r'l ~I N
~t3 ~ ~ ~?`~?`
m t~ uN t~ m
~w aO Iq t~ o ~ ~ 8
O tr_ U ~, t~ t~ 3~ 0 ~ ~ ~ UD U y ~ ~o U
Cl 'r ql' t~ 1 r l r l N ~ ~ N
` 1 ~ 11 X X ~ 1 X ~ X :1:
t~ U U U ~ t~ t~ t~ tJ ~ U t~ t~ U t~ t~ U
E
~ tq t~ Q ~ t7 ~: ~ O n,
X 1`1 ~ N N 1`1 1`1 N N 1`1 `1 ~ `1 ;~ N ~
. 7 3 ~
~25~ 7~1
--56--
o
~ ~ ~ O;~ ~ ~
3g N '~ ~ -
r~ 0~
7 ~ 38`or
m ~ ~ ~ ~ o ~ tQ 1 ~ w ~ n m ~ 5~
~q ~ 11 ~ .
;~ ¦ n s ~Q a s E ~ Q ~ E S
Z s~ :E S æ ~ æ
;~¦ N N N N ~ U U~ U =r-
t~
~ I I I I I I I X~ I ~ I I I I I
~ r-
¦ ~ X I U~ o $
11: N ~ 1'1
U ' U U ~ ~ ~ ~ ~ U ~ ~ ~ U
~1
~ D ~ N ~¢ ttl 'J O W 4
~5~31D7~
-57-
C. From the Compounds of Formula VI
A solution of 10 g. (0.022 mole) of 2-methyl-3-(4-
methoxybenzoyl)-1-[2-(p-toluenesulfonyloxy)ethyl]-lH-indole
(Preparation 7A) and 8.74 g. (0.086 mole) of 4-hydroxy-
piperidine in 50 ml. of dry acetonitrile was heated under
reflux for about forty eight hours, and the mixture was
then diluted with ethyl acetate and washed with water. The
organic layer was extracted with 2N hydrochloric acid, then
with water, and the combined aqueous washings were com-
bined, basified with 10% sodium hydroxide and extracted
with ethyl acetate. The combined organic extracts were
dried over magnesium sulfate, filtered and concentrated to
dryness to give the product, in the form oE the free base,
as a brown oil. The latter was converted to the hydro-
chloride salt in ethyl acetate and ethereal hydrogen
chloride to give 2.6 9. (27%) of 2-methx1-3-(4-methoxy-
benzoyl)-1-[2-(4-hydroxy-1-piperidi_yl)ethyl]-lH-indole
hydrochloride hemihydrate, m.p. 226-229C.
Examples 3B - 3AM
Following a procedure similar to that described in
Example 3A above, the following species of ~ormula I in
Table 3 below were prepared by reaction of a 2-methyl-3-R3-
carbonyl-l-t2-tosyloxyethyl)-lH-indole or a 2-methyl-3-R3-
carbonyl-l-(halo-lower-alkyl)-lH-indole of formula VI with
an appropriate amine, HN=B, where R2, in each instance, is
CH3. The starting material in each of Examples 3B-3V, 3AK
and 3AM was the corresponding 1-(2-tosyLoxyethyl)-lH-
indole in Bxample 3W the corresponding 1-(3-chloro--
3~ propyl)-lH-indole; and in each of Examples 3X-3AJ and 3AL
the corre~ponding 1-(bromo-lower-alkyl)-lH-indole.
~- D.~ 7356A
~L~2515169~
--58--
~ ~ ~, r ~ O ~ U 1, u ~, ~
` ~ ~ X ~ R 5
r~ ~ O
ùS u u u ~ n Q ~ a Q t~ a u a o a a ~a u Q
U~ ~T~
2 ~ r Z 2: rl ~ Z ~ ri
r~ rl r r~ r~ r~ r~ r~ r~ r~ r~ r~ r~ ~ r~ rl rJ rl r~
I ~ ~ ~ ~ ~ ~ ~ - X i ~ ~ ~ ~ ~, ~ X X X
~flUUYY5~,yu y,y,uy,yy ouy,y,ut~
r~
~ X ~ ~ X ~: X
t~ u ~ u ~ ~) u ~ u ~
O O In ~O O ~ ~ ~ O O ~ O O O O O O O
~ U r~ r~ fi.& ~ xr'~- r~ r~ ~ xr' x
,,~ u u, ~ ~ y y ,3~ S ~ ~ ~ Y
E I
~ ¦ m ru, ~ w ~v ~ E 2 ~ Q Cl ~ ~ ~
D.IJ. 73:.~o~
--59 ~
I o ~ o ~ ~ ~o O ~ P o o ,~ ~ rJ
O ~ 1
~ U ~ ~3 ~
; P ~ o ,. o U C~ ~ p ~ ~ p p~
: Dl~ h 14 114 14 04 ~ h P~- h h h b. b- h 14 h h
dS a n a a a Q n n a q Q n a Q a n n n a ;~ ~ ~ 8.~ ,~
~ u-- u-- u u u u-- u ~u-- u u u-- u-- u-- u-- ~u- u-- u-- u-- u-- ~ ~ ~
UUU~UVUUUUUUUUUUUU~'C~ V~O
O o o D o o o o o O O o ~ o o o O O ~ ~ ~ a ~, ~ O
~ " ", ,~ 3~ ~ C ~ ~ j D ~ S
O;rt U~ y ~ ,~ u~ U~ ct U~ u~ U~ ~ ~ Ul u~
~1
~ ¢ m U a ~ h V t~
~Y a ~; 3 ~ ¢ ~ ¢ ~C ¢
I_~J. 1~56A
~25~
-60-
D Miscellaneous Processes
.
Example 4A
Following a procedure similar to that described in
Preparation3above,8.0g. (0.02mole) of2-methyl-3-(3-nitro-
benzoyl)-1-[2-(4-morpholinyl)ethyl]-lH-indole (ExamplelAD)
in 175 ml. of ethyl acetate and 75 ml. of acetic acid was
reduced with hydrogen in a Parr shaker over 0.3 ~. of
platinum oxide. The product was isolated in the form of
the free base and recrystallized from ethyl acetate to give
6.0 9. (83%) of 2-methyl-3-~3-aminobenzoyl)-1-[2-(4-morpho-
linyl)ethyl]-ll-l-indole, m.p. 167-169C.
Example 4B
Following a procedure similar to that described in
Example 4A above, 28 9. (0.07 mole) of 2 methyl-3-(4-nitro-
benzoyl)-1-[2-(4-morpholinyl)ethyl~-lH-indole (Example
lCQ) in 100 ml. of glacial acetic acid and 100 ml. of ethyl
acetate was reduced with hydrogen over platinum oxide and
the product, in the form of the free base, was recrystal-
lized from ethyl acetate to give 19.05 9. (75~) of 2-
m.p. 154-156C.
A small amount of the free base was reacted with
methanesulfonic acid and the product recrystallized ~rom
ethanol to give the corresponding methanesulfonate as
an orange powder, m.p. 221-223C.
D.N 7~oA
~25~
-61-
Exam~le 4C
To a stirred suspension of 2.5 g. (0.0059 mole~
o~ 2-methyl-3-(4-nitroben7oyl)-6-methoxy-l-[2-~4-morpholinyl)-
ethyl~lH-indole (Example lAN) and 2 g. (0 03G mole) of
iron filings in 25 ml. of 50% aqueous ethanol in a three~
necked flask equipped with a reflux condenser and a stirrer
was added, over a five minute period with stirring, 0O93
ml. of a solution containing 5 ml. of concentrated hydro-
chloric acid in 25 ml. oE 50% aqueous ethanol. Wlen
addition was complete, the reaction mixture was heated
under reflux for two and a halE hours, then cooled and made
basic with 15~ alcoholic potas~ium hydroxide solution. The
mixture was filtered, the filtrate was taken to dryness ln
vacuo, and the oily product was dissolved in methylene
dichloride and the organic solution washed first with
alkali, then with water and then with brine and dried over
magnesium sulfate. Filtration of the solution and concen-
tration to dryness afforded an oil which, on trituration
with ethyl acetate/diethyl ether, crystallized to give 1.4
g. ~71%) of 2-methyl-3-(4-aminobenzoyl)-6-methoxy-1-[2-(4-
morpholinyl)ethyl]-lH-indole, m.p. 126-128C.
_ L~. 7356A
71~
-62-
Example 4D
Following a procedure similar to that described
in Example sc above, 7.3 g. (O.OlB mole) of 2-methyl-
3-(4-nitrobenzoyl)-1-[1-methyl-2-(4~morpholinyl)ethyl]-lH-
indole ~Example 2K), dissolved in 75 ml. of 50~ ethanol,
was reduced with 6 y. (0.11 mole) of iron filings and 2.8
ml. of a solution containing 5.2 ml. of concentrated hydro-
chloric acid in 25 ml. of 50~ ethanol. The product was
isolated in the form of the free base to give 3.7 g. (54~)
of 2-methyl-3-(4-aminobenzoyl~_-1-[1-meth~1-2-~-morpho-
linyl~ethyl]-lH-indole, m.p. 192-195C.
F.xample 5A
To a solution of 4.0 g. (0.01 mole) of 2-methyl-
3-(4-aminobenzoyl)-1-[2-(4-morpholinyl)ethyl]-lH-indole
(Example 4B) in 20 ml. of glacial acetic acid was added 2.3
ml~ ~0.023 mole) of acetic anhydride and 2 drops of con-
centrated sulfuric acid. The mixture was warmed slightly,
then poured into water and the aqueous mixture basified by
addition of 10% sodium hydroxide. The gum which separated
was isolated by decantation, triturated with water to
produce a solid material which was collected and recrystal-
lized from ethyl acetate to give 2.3 g. (56%) of 2-methyl-
3~(~-acetylaminobenzoyl)-1-[2-54-morpholinyl)ethyl]-lH-
indole, m.p. 173.5-174.5C.
L~l. 7356A
~ ~5
-63-
Examples 5B-SF
Following a procedure similar to that described in
Example 5A above~ the following compounds of formula I in
Table 5 below were prepared by acylation of an appropriate
S 2-methyl-3-(aminobenzoyl)-1-aminoalkyl-lH-indole. In each
instance, R2 is CH3; R4 is hydrogen; Alk is (CH2)2; and N=B
is 4-morpholinyl. All compounds were isolated and charac-
terized as the free bases. The acylating agent and the
reaction solvent are given in the column headed i'AcX/Solv.
i).~l. 7 1 ~fj ~
3~5~
~4-
I
; ~ ~ ~ ,1 ~
~' ~
fi~ t
,-,
~1
O ~ u~
~ 5~
u~ UD U U9 UD z D
V c~ nJ
~ u, m~ ~ f ~ ~
f~;~
~ m o f~
~ .
D. ~ 7356A
7~
-65-
Example 6
Following a procedure similar to that described
in Preparation 3 above, 14.0 g~ (0.03 mole~ of 2-methyl-
3 (4-benzyloxybenzoy~ [2-(4-morpholinyl)ethy~ H-
indole (~xample lAG) in 250 ml. oE ethanol was reduced
with hydrogen in a Parr shaker over 1.0 g. of 5~ palladium-
on-charcoal. The product was converted to the hydro-
chloride salt which was recrystallized from water to give
11.1 g. (92%) of 2-methyl-3-~4-hydroxybenzoyl~-1-[2-(4-
~ l)ethyl~-lH-indole hydrochloride, m.p 236-
2B8C.
Example 7
A mixture of 7.S g. (0.02 mole) of 2-methyl-3-
(4-cyanobenzoyl)-1-12-(4-morpholinyl)ethyl~-lH-indole
(Example lAF), 100 ml. of ethanol, 15 ml. of liquid ammonia
and 2 tablespoons of a Raney nickel in ethanol suspension
was heated in an autoclave at 50C. under an initial
hydrogen pressure of 320 p.s.i.g. The mixture was then
cooled, the catalyst was removed by Eiltration, and the
solution was taken to dryness in vacuo to give 7.2 9. of
product as a green foamy material which was converted to
the hydrochloride salt to give 1.7 9O (19~) of 2-methyl-3-
~4-aminome~ylbenzoyl)-1-[2-~4-morpholinyl)ethyl]-lH-indole
dihydrochloride, m p 196-208C.
u ~ ~
-66-
Exam~le 8A
A mixture of 10.4 g. (0.023 mole) of 2-methyl-3-[4-
~N-trifluoroacetylamino)benzoyl3-1-[2-(4-morpholinyl)ethyl]-
lH-indole (Example 5C), 20 g. ~0.20 mole) of potassium
carbonate and 5 ml. (11.4 9., 0.08 mole) of methyl iodide
in 100 ml. of acetone was heated under reflux with stir-
ring Eor two hours and then taken to dryness to yield
a yellow foam, which was partitioned between water and
chloroform and extracted twice with chloroform. The
combined extracts were washed with brine, filtered and
taken to dryness to give a yellow oil which was dissolved
in isopropanol and treated with excess hydrogen chloride
followed by additional isopropanol. The solution was
diluted with ether, and the solid which separated was
collected and dried to give 4.6 9. of 2-methyl-3-[4~
methyl N-trifluoroacetylamino)benzoyl]-1-[2-(4-morpholinyl)-
ethyl]-lH-indole hydrochloride, m.p. 224-226C.
The latter (3.7 g., 0.007 mole) was mixed with
25 ml. oE 10~ sodium hydroxide, and the mixture was heated
under reflux for one hour. On cooling, a solid separated
from the mixture which was collected, dissolved in isopropanol
and treated with excess hydrogen chloride and isopropanol.
The solid which separated was collected and recrystallized
from methanol/diethyl ether to give 1.2 g. (37%~ oE 2-
methyl-3-(4-methylaminobenzoyl)-1-[2-(4-morpholinyl)-
ethyl]-lH-indole dihydrochloride hemihydrate, m.p~ 190-
192C.
D.,~ 735h~
'7
-67-
xample 8B
Following a procedure similar to that described
in Example 8A/ 22 g. (0.049 mole) of 2-methyl 3-[4-(N-
trifluoroacetylamino~benzoyl3-1-[2-(4-morpholinyl)ethyl]-
S lH-indole ~Example 5C) was reacted with 35.9 g. (0.129
mole) of butyl iodide in 250 ml. of acetone in the pres-
ence of 48 g. (0.343 mole) of potassium carbonate and
the resulting 2-methyl-3-[4-~N-butyl-N-trifluoroacetyl-
amino)benzoyl]-1-[2-t4-morpholinyl)ethyl]-lH-indole (24
g., 98%J hydrolyzed by refluxing in a solution of 500
ml, of 10% sodium hydroxide and 100 ml. of ethanol.
The resulting crude product was chromatographed on silica
gel, eluting with 25~ acetone-hexane. The higher RE
material was collected and dried to give 2.6 g. of 2-
methyl-3-(4-butylaminobenzoy~ 2-(4-morp~olinyl)eth~
lH-indole, m.p. 129.0-130.0C.
-
D.N. ~GA
~ 2~ ~ ~7
-68
_ample 9
To a stirred suspension of 1200 g. (0.03 mole)
of 2-methyl-3-~4-aminobenzoyl)-1-[2-~4-morpholinyl)ethyl]-
lH-indole (Example 4B) in 15 ml. of glacial acetic acid
and 30 ml. of water was added a solution of 4.5 g. (0.06
mole) of sodium isocyanate in 30 ml. of water. The mix-
ture was stirred at room temperature for two hours, then
diluted with water and made alkaline with 10~ sodium
hydroxide. The solid which separated was collected and
recrystallized from DMF to give 5.9 g. (48%) of 2-methyl-
3~(4-carbamylaminobenzoyl~ [2-(4-morpholinyl)ethyl]-
lH-indole, m.p. 192-202C.
Example 10
To a stirred suspension of 3.77 g. (0.01 mole)
of 2-methyl-3-(4-aminomethylbenæoyl)-1-[2-(4-morpholinyl)-
ethyl}-lH-indole (Example 7) in 30 ml. of toluene was
added a solution of dimethyl cyanocarbonimidodithioate
in 20 ml. of toluene. The mixture was stirred for an
hour and a half, and the solid which separated was col-
lected and dried to give 4.75 g. of the corresponding
3-(4-aminomethylbenzoyl)-N-(methyl cyanocarbonimidothioate).
The latter (4.0 g., 0.008 mole) r in 75 ml of
isopropanol and 25 ml of liquid ammonia, was heated in
an autoclave for one hour at 100C. The reaction ~ixture
was then filtered, allowed to evaporate to dryness, and
the resulting pale yellow foam was recrystallized from
acetonitrile to give 2.3 9. (65~) of 2-methyl-3-(4-cyano-
gua_idinylmethylbenzoyl~-l-[2-(4-morpholinyl~ethyl]~
indole, m.p. 191.5-195C.
____
D.il. ~ B
51~6~7~
--ss--
Example 11
A mixture oE 10 9. (0,027 mole) of 2-methyl-3-~4-
cyanobenzoyl)-1-[2-(9-morpholinyl)ethyl]-lH-indole
tExample lAF~, 20 g. (0.19 mole) of sodium hypophosphite,
50 ml. oE water, 50 ml. of glacial acetic acid, 100 ml. of
pyridine and two spatulas of Raney nickel was heated to
about 40C. Eor two and a half hours and then filtered.
The filtrate was taken to dryness in vacuo, and the result--
ing oil was washed with toluene and again concentrated to
dryness to remove residual pyridine. The residual oil was
suspended in aqueous alkali and extracted with ethyl
acetate. The combined organic extracts were washed with
brine, dried over magnesium sulfate, filtered and concen-
trated to dryness to give an oil which was recrystallized
from ethyl acetate to afÇord 1.5 9. (15-~) of 2-methyl-3-
(4~formylbenzoyl) 1-[2-(4-morpholinyl~ethyl~-lH-indole,
m.p. 149-150C.
Example 12
A mixture of 2.5 g. (0.006 mole) of 2-methyl-3-
~4-formylbenzoyl)-1-[2-(4-morpholinyl)ethyl]-lH~indole
~Example 11), 0.55 9. ~0.0067 mole) of sodium acetate and
0.51 9. (0.0073 mole) of hydroxylamine hydrochloride in 2~
ml. of ethanol, 5 ml. of methanol and 6 ml. of water was
heated under reflux for one hour and then concentrated to
dryness in vacuo. The residual solid was collected, washed
with water and diethyl ether to give 2.5 g. (95%) of 2-
y__3~ y_roxyilllinomet~ --ox -1-[2-(4-morphol nyl)-
ethyl]-lH-i_dole, m.p~ 184-186C.
r~. .i . ~,.~
~L2S~3~7~t
-70-
Exam~le 13A
A mixture of 20 g. (0.053 mole) of 2-methyl-3-
(4-methoxybenzoyl)-1-[2-~4-morpholinyl)ethylJ-lH-indole
(Example lB) and 20 g. (0.29 mole) of hydroxylamine hydro-
chloride in 100 ml. of pyridine was heated under reflux for
about twelve hours and then diluted with methylene
dichloride. The organic mixture was washed five times with
water, then with brine, dried over magnesium sulfate, fil- ~
tered and taken to dryness in vacuo to give a dark green
oil which was washed three times with toluene and again
concentrated to dryness in vacuo. Trituration oE the
residue with ethyl acetate/diethyl ether afforded crystals
which were collected to give 9.5 g. (46%) of 2-methyl-3-(4-
methoxxbenzoyl)-1-[2-(4-morpholinyl)ethyl]-lH-indole
oxime, m.p. 166-169C.
Example 13B
Following a procedure similar to that described in
Example 13A above, 44 g. (0.101 mole~ of 5-fluoro-3-(2-
fluorobenzoyl)-2-methyl-1-[3-(4-morpholinyl)propyl]-lH-indole
(Example 2~B) was reacted with 70.3 g. (1.01 moles) of
hydroxylamine hydrochloride in 500 ml of pyridine and the
product recrystallized from acetonitrile to give 1505 9.
(37~) of 5-fluoro-3-(2-fluorobenzoyl~-2-methyl-1-[3-(4
morpholinyl)propyl]-lH-indole oxime, mOp. 150-162~C.
_ D.N. ~ A
P~
-71-
Exa~ple 13C
Following a procedure similar to that described in
Bxample 13A above, in two runs a total of 28~3 9. (0.77
mole) of3-~2-fluorobenzoyl)-2-methyl-1-[2-(4-morpholinyl)-
ethyl]-1~-indole (Example lZ) was reacted with a total o~
53,7 g. (0.77 mole) of hydroxylamine hydrochloride in a
total of 575 ml. of pyridine to give a total of 24.4 g. of
crude product. The latter was dissolved in a solution of
54.1 9. of sodium methoxide in 500 ml. of methanol, and
the solution was heated under reflux or forty-eight hours
and then taken to dryness ln vacuo. The residue was par-
titioned between chloroform and water, and the chloroEorm-
soluble material was flash chromatographed on silica gel
eluting with 98:2 chloroform:isopropanol. The slower mov-
lS ing material was isolated and recrystallized from toluene-
hexane to give 8.0 9. (33~) of CE) 3-~2-fluoroben~oyl)-2-
methyl~l-[2-(4-moepholinyl)ethyl]-lH-indole oxime, m p
160 167C.
Example 14
A mixture of 8 9. (0.022 mole) of 2-methyl-3-(4-
aminobenzoyl) 1-~2-(4-morpholinyl)ethyl]-lH-indole
(Example 4B) and 4.28 ml. (0.033 mole) of 2,5-dimethoxy-
tetrahydrofuran in 40 ml. of glacial acetic acid was heated
under reflux for one hour and then poured into an ice/wa~er
mixture. The mixture was rendered alkaline by addition of
10% sodium bicarbonate solutiont and the solid which
separated was collected and dissolved in methylene
dichloride. The organic solution was dried over magnesium
~5i3at76:~
-72-
sulfa~e, filtered and the filtrate concentrated to dryness
ln vacuo and then chromatographed through a pad of
Florisil, eluting with methylene dichloride. There was
thus obtained 4.5 g. of an oil which, on trituration with
diethyl ether, afforded a light yellow powder which was
collected to give 3.5 g. (38~) of 2-methyl-3-[4-(lH-pyrrol-
l-yl)benzoyl~ [2-(4-morpholiny~)ethyl]-lH-indole, m.p.
125-127C.
Example 15
To each of three 14 liter fermentors contailling 10
liters of soybean meal/dextrose medium (containing 5 g./
liter of soybean meal, 5 g./liter of brewer's yeast, 5 9./
liter of dipotassium hydrogen phosphate and 20 g./liker o~
dextrose) at pH 6.4, was added 2.0 9. (0.016 mole total) of
2-methyl-3-(4-methoxybenzoyl)-1-12-(4-morpholinyl)ethyl]-lH-
indole ~Example lB), and the mixtures were cultured for
five days in the presence of Fusarium solani ~Mart.) with
stirring at 400 rpm at a temperature of 26-27C. while
sparging with air at 5 liters per minute. The mixtures
were then separately extracted with 20 liters of methylene
dichloride using 20 liters per fermentor, and the combined
extracts were concentrated to 20 litees. The concentrate
was washed first with 2 liters of 0.05N sodium hydroxide,
then two times with 2 liters of water, and the organic
layer was concentrated to about 1 liter, dried over sodium
sulfate, charcoaled, filtered and further evaporated to
dryness to give an oily residue which solidified on cool-
ing. The latter was recrystallized from acetone/diethyl
ether to give 2.7 g. (43%) of 2-methyl-3-~4-methoxy-
benzoyl~ [2-~4-morpholinyl)ethyl]~lH-indole/N(MOR)~oxide,
m.p. 142-144C.
. . .
D . N . ~ oA
8~7 0
-73-
Ex~ e 16A
A mixture of 38.3 9. (0.10 mole) o 2-methyl-3-
(2-methoxybenzoyl)-1-[2-(4-morpholinyl)ethyl]-lH-indole
(Example lU) and 35.2 9. (0.31 mole~ of pyridine hydro-
chloride was heated in an oil bath at 210C. for four hours
and the mixture allowed to cool. The solidified reaction
mixture was partitioned between ethyl aceta~e and aqueous
sodium carbonate by warming on a steam bath, ~nd the
organic layer was separated, taken to dryness and subjected
to high performance liquid chromatography on a silica yel
column in 1:] hexane:ethyl acetate. The first 7 liters of
eluate were discarded, and the next 8 liters were col-
lected, taken to dryness and the residue recrystallized
from isopropanol to give 3.33 g. (23%) of 2-methyl 3-(2-
hydroxybenzoyl)-1-[2-( -morpholinyl)ethyl]-lH indole, m.p.
115-116C.
Example 16B
Following a procedure similar to that described in
Example 16A, 15.8 g. t0.035 mole) of 5~fluoro-2-methyl-3-
(4-methoxybenzoyl)-1-13-(4-morpholinyl~propyl]-lH-indole
hydrochloride (Example lI) was heated with 20.4 9. (0.176
mole) of pyridine hydrochloride at 210C. in an oil bath
for two hours, and the product isolated as the hydro-
chloride salt to give 9.2 9. (67%~ of 5-fluoro-2 methyl-3-
~4-hydroxybenzoyl~-l-l3-~4-morpholinyl)propy~ H-indole
hydrochloride, m.p. 290-232C. (from DMF-ether).
D. ,735~A
2~ ~ ~7
-74-
Exa~ple 17
A mixture of 1.9 g. ~0.005 mole) of 2-methyl-3-
(4-aminomethylbenzoyl)-1-12-(4-morpholinyl)ethyl~-lH-
indole (Example 7), 0.7 g. (0.0025 mole) of 2-methy]-2-
5 thiopseudourea sulfate and 10 ml of water was heated on asteam bath for two hours and then filtered. The filtrate
was taken to dryness, and the residue was recrystallized
from methanol to give 1.0 g~ (85~) of 2-methyl-3-(4-
guanidinylmethylbenzoyl)-1-[2-~4-morpholinyl)ethyl]-lH-indole
sulfate (2:1) r ~.p. 170-180C
.
Example 18
Following a procedure similar to that described
in Rreparation 3 above, a solution of 0.9 g. (0.0019 mole)
of 6-benzyloxy-2-methyl-3-(4-methoxybenzoyl)-1-[2~(4-morpho-
linyl)ethyl]-lH-indole (Example lBK) in 200 ml. of methanol
was reduced with hydrogen over three spatulas (approxi-
mately 1.5 g.) of 10% palladium-on-charcoal under a
hydrogen pressure of 50 p.s.i.g. at ambient temperature in
a Parr shaker. The product was isolated in the form of the
hydrochloride which was recrystallized from ethyl acetate-
diethyl ether to give 0.35 g. of 6-hydroxy-2-methyl-3-(4-
methoxybenzoyl)-1-[2-(4-morpholinyl)ethyl]-lH-indole hydro-
chloride ~ydrate (3:41, m.p. 185-187C.
D. 1 7356A
~51~t~7~
Example 19
To 70 ml. of dry DMF was added, dropwise with stir-
ring, 15 ml. of phosphorus oxychloride while cooling in an
ice bath. The mixture was then treated with a solution of
24.4 g. (0.10 mole) of 2-methyl-1-[2-t4-morpholinyl)-
ethyl3-lH-indole (Preparation 4A) in 50 ml. of DMF while
continuing to cool in an ice bath. When addition was com-
plete, the mixture was stirred for about one hour and then
poured into 50 ~. oE ice to give a clear solution which was
chilled to about 20C. and basified by the addition of 150
ml. of 35~ potassium hydroxide. The mixture was warmed to
about 70, then chilled in an ice bath, and the solid which
separated was collected, dried and recrystallized from
ethyl acetate to give 23.3 9. (86%) of 3-formyl-2-methyl-1-
12-(4-morpholinyl) ethyl]-lH-indole, m.p. 115-116C.
A solution containing 13.6 g. (0.05 mole) of the
latter and 9.0 g. (0.06 mole) of 4-methoxyacetophenone in
50 ml. o~ absolute ethanol was treated with 500 ml. of
3.7N ethanolic hydrogen chloride in a thin stream, while
stirring, and the resulting red solution was stirred for
twenty-four hours. The solid which separated was collected
by iltration, washed with absolute ethanol and then
recrystallized first from methanol and then from S0~
ethanol to give 5~3 9. (24%) of 1-~2-methyl-1-[2-~4-morpho-
linyl)ethyl]-lH-indol-3-yl~-3-(4-methoxyphenyl)propen-3-one
monohyd ochloride, m.p. 259-262C.
.
1~. 7356A
~5~307~
Example 20A
Following a procedure similar to that described
inExamplel9 above,3-acetyl-2-methy~ 4-morpholinyl)-
ethyl]-lH-indole was prepared by reaction of 12 g. (O.OS
mole) of 2-methyl-1-[2-(4-morpholinyl)ethyl]-lH-indole
~Preparation 4A) with 10 ml. (0.11 mole) of phosphorus
oxychloride in 25 ml. of dimethylacetamide. The product
was dissolved in isopropanol and the solution treated with
ethereal hydrogen chloride to give 6 g. (37%) of the
product as the hydrochloride salt, m.p 249-253 ~C.
To a solution of 6 g. (0.107 mole) oE potassium
hydroxide pellets in 350 ml. oE absolute ethanol was added
15 g. (0.047 mole) of the latter and 19 g. (0.14 mole) oE 2-
methylbenzaldehyde. The mixture was heated under reflux
for one and a half hours, concentrated to dryness and the
product, in the form of the free base, recrystallized once
from ethyl acetate and once from isopropanol to give 7.9 g.
(41~) of 3-(2-methylcinnamoyl)-2-methyl-1-[2-~4-morpho-
linyl)ethyl]-lH-indole, m.p. 131-135C.
Example 20B
Following a procedure similar to that described in
Example 20A above, 14.75 g. (0.0516 mole) of 3-acetyl-2-
methyl-l-[2-(4-morpholinyl)ethyl]-lH-indole (Example 20A)
was reacted with 2-fluorobenzaldehyde in 260 ml. of ethanol
in the presence of 3.44 g. (0.061 mole) of potassium
hydroxide pellets and the product, in the form of the free
base, recrystallized from ethyl acetate to give 10.0 g.
(54~) of 3-(2-fluorocinnamoyl)-2-methyl-1-[2-(4-morpho-
lin~Lethyl]-lH~indole, m.p. 113-116C.
~25~307
~77--
Example 21
A solution of 11 9. (0.025 mole) of 1-[2-(3-hydroxy-
l-piperidinyl~ethyl]-2-methyl-3-(4-methoxybenzoyl)-lH-indole
(Exa~ple 3s) in 50 ml. of pyridine and 25 ml. of acetic
anhydride was allowed to stand at ambient temperature for
about forty-eight hours and the mixture then poured into
ice water. The oily solid which separated was collected,
dissolved in ethyl acetate and the solution washed first
with dilute sodium hydroxide, then with brine, dried and
taken to dryness. The residue was dissolved in ethyl
acetate, the solution treated with 3.67 g. of maleic acid,
the mixture heated to boiling to dissolve all solid, then
cooled, and the solid which separated was collected and
recrystallized once again Erom ethyl acetate to give 8.12
9. ~59~) of 1~[2-~3~acetoxy~1~piperidinyl)ethyl]~2~methyl~
3-(4-methoxy~enzoyl)~lH~indole maleate (1:1), m.p. l61~
161.5C.
Example 22
To a stirred solution of 12.5 g. (0.03 mole) of 2~
methyl~3-(4~methoxybenzoyl)-1~[2~(1~piperazinyl~ethyl]~lH-
indole (Example lL)in 150 ml. of pyridine was added, with
stirring while cooling in an ice bath, 7.1 g. (0.066 mole)
of ethyl chloroformate. When addition was complete, the
solution was stirred in an ice bath for thirty minutes,
then allowed to stand at ambient temperature for about
eighteen hours and then poured into ice water. Extraction
of the mixture with ethyl acetate afforded the crude
product in the form of the free base which was dissolved in
ethyl acetate and converted to the maleate salt by addition
of 2.6 9. of maleic acid. The latter was recrystalli~ed
from ethyl acetate-ether to give 7.6 9. (41%) of 1-~2-14-
D.N. ~356A
-7S~
carbethoxy-l-piperazinyll~thy~ 2-m-thyl-3-~4 ~ y~
benzoyl)-lR-indole maleate (1:1~, m.p. 155-156~C.
Exam~le 23A
A solution of 12.5 g. (0.033 mole) of 2-methyl-3-(4-
5 methoxybenzoyl)-1-[2-(1-piperazinyl)ethyl~-lYi-indole
(Example lL) in 150 ml. of pyridine was cooled in an ice
bath and treated with 50 ml. of acetic anhydride and the
solution allowed to stand at ambient temperature for about
eighteen hours. The solution was then poured into ice
water and the mixture extracted with ethyl acetate. The
organic solution, on washing with brine, drying over sodium
sulfate and evaporation to dryness, afEorded the crude
product which was taken into ethyl acetate and the solution
treated with 4.~ g. of maleic acid. The solid which
separated was collected and recrystallized from ethanol to
give 7.36 g. (42~) of 1-~2-(4-acetYl-l-piperazlnyl)=
ethyll-2-methyl-3-t4-methoxybenzoyl)-lH-indole maleate
(1: 1 ) r m.p. 147.5-152C.
Example 23B
Following a procedure similar to that described
above in Example 23A, 11.9 9. (0.029 mole~ of 5-fluoro-2-
methyl-3-(4~methoxybenzoyl)-1-[3-(1-piperazinyl)propyl]-
lH-indole tExample lBN) was reacted with 50 ml. of acetic
anhydride in 150 ml~ of pyridine and the product isolated
in the form of the methanesulfonate salt to give 6.6 9.
(41%) of 5-fluoro-2-methyl-3-14-metho~_nzoyl)-1 [3-(4
acetyl-l-piperazinyl)~ropyl]-lH-indole methanesulfonate,
.p. 170-171~C.
1258070 D.~7356A
-79-
Example 24
A solution of 15 g. (0.04 mole) of 2-methyl-3-(4
aminobenzoyl)-1-[2-(4-morpholinyl)ethyl]-lH-indole
(Example 4B), 12 9. (0.4 mole) of formaldehyde and 7.5 g.
S (0.119 mole) of sodium cyanoborohydride in 250 ml. of
acetonitrile was stirred for thirty minutes and then
treated dropwise with acetic acid until acidic. The mix-
ture was stirred for about eighteen hours, then poured into
aqueous potassium hydroxide and the mixture extracted with
ether. The organic extracts, on drying over magnesium sul-
fate and concentration to dryness, afEorded a yellow solid
which was recrystallized from isopropanol to give 7.5 9.
(48~) oE 3-~4-dimethylaminobenzoyl)-2-methyl-1-[2-54-
morpholinyl)ethyl]-lH-indole, m.p. 152-154C.
Example 25A
A solution of 19.1 9. (0.047 mole) of 1-(3-bromo-
propyl)-5-fluoro-2-methyl-3-(4-methoxybenzoyl)-lH-indole
(Preparation 7D) in 500 ml. of acetone and 50 ml. of water
was treated with 3.05 9. (0.047 mole) of sodium azide and
the mixture heated under reflux or about eighteen hours
and then taken to dryness in vacuo. The residue was
partitioned between ethyl acetate and water, and the
organic layer separated, washed with brine, taken to dry-
ness and the residue recrystallized from isopropanol to
give 10.3 g. (60%) of 1 ~3-azido~ro~lL~5-fluoro-2-methyl-
3-(4-methoxybenzoy~ -indole, m p 69-73
.
D.l~. 73~6A
~25~7~
-80-
The latter (0.028 mole) was dissolvedl in 265 ml~ of
ethanol and 35 ml. of THF and reduced with hydro~en over
1.0 g. of 10% palladium-on-charcoal in a Parr shaker. When
reduction was complete, in about ~our hours, the mixture
was filtered, the filtrate taken to dryness and the residue
dissolved in ethyl acetate and treated with 3.13 9. of
maleic acid and heated to dissolve all the material. The
solid which separated was collected and recrystallized from
isopropanol to give 9.7 g. (76%) of 1-(3-aminopropyl)-5-
f ro-2-methyl-3-(4-methoxybenzoyl)-lH-indole maleate (1:1),
. p. 16g-171 C .
~xample 25B
Following a procedure similar to that described in
Example 25A above, 13.98 g. (0.03 mole) of 2-methyl-3-(4-
methoxybenzoyl)-1-(2-tosyloxyethyl)-lH-indole (Preparation
7A) in 325 ml. of acetone and 32.5 ml. of water was reacted
with 1.96 g. (0.03 mole) of sodium azide and the product
recrystallized from isopropanol to give fi.l g. (61%) of 1-
~ ~t3~31=3=~ethyl-3-(4-methoxyben~yl)-lH-indole,
2~ m-p- 91-93C.
The latter (0.024 mole), dissolved in 250 ml. of
ethanol and 50 ml. of THF, was reduced with hydrogen over
008 9~ of 10~ palladium-on-charcoal at 47 p.s.i.g. and the
product isolated in the form of the maleate salt to give
7.6 9. ~75%) of 1-(2-aminoethyl)-2-methyl-3-~4-methoxy-
benzoyl~-lH-indole maleate, m.p. 165-166C.
Example 26A
A mixture of 10 g. ~0.027 mole) of 3-(4-fluoro-
benzoyl)-2-methyl-1-[2-(4-morpholinyl)ethyl~-lH-indolev
D 13~A
-81-
~Example lQ) 2.5 9. (0.033 mole1 of 2-methoxyethylamine
and 7.6 9. (0.054 mole) of potassium carbonate in 15 ml.
of ~MS0 was heated at 95C under nitrogen and the mixture
then poured into ice water. The solid which separated was
collected, dissolved in methylene dichloride and the
solution washed with brine, dried over magnesium sulfate,
filtered and taken to dryness in vacuo. Recrystallization
of the residue from ethyl acetate-ether afforded 4.2 g.
l37~) of 2-methyl-3-[4-(2-methoxyethylamino)benzovl]-l-[2
(4=morpholinyl)ethyl]-lH-indole, m.p. 121-123G.
Examples 26~-26I
Following a procedure similar to that described in
Example 26~ above, reaction of a 3-(4-halobenzoyl)-2-
methyl-l-[2-(4-morpholinyl)ethyl]-lH-indole with an
. appropriate amine in the presence of potassium carbonate
afforded the species of Eormula I in Table 26 where, in
each instance, R2 is CH3; and N=s is 4-morpholinyl. The
species of Examples 26B-26D, 26G and 26H were obtained from
the corresponding 4-Eluorobenzoyl starting material, and
the species of Examples 26E, 26F and 26I were obtained from
the corresponding bromobenzoyl (or bromonaphthyl) starting
materials.
D._.; 7356A
-- ~25~C17~
--82--
tO ~0 ~
~ ~0
O
O O
m ~ ~ ~ ~q m ~ m
I o o o o o
u, a a n n a a a a
'~
.
P~
~ ~ u u '~ , V
E~,
~.
I II .~.
o ;~ U ;~
U ~ u
~1 .
p~ V Q ~ ~
X ~ tQ ~ ~O ~O ~ d
~1 ~ ~ ~ ~ ~ c~
~ 7
-83-
Example 27A
A mixture of 8.2 9. (0.02 mole) oE 1--[2-(4-Eormyl-l-
piperazinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-lH-indole
(Example 3S) and 2.06 g. (0.052 mole) of sodium hydroxide
in 100 ml. of ethanol and 80 ml. of water was heated under
reflux for our hours, then poured into ice water and
extracted with ethyl acetate. The organic solution was
washed with brine, dried over sodium sulfate, taken to dry-
ness and the residue dissolved in ethyl acetate. The
solution was treated with an excess of a lN solution oE
methanesulfonic acid, and the solid which separated was
collected and recrystallized from ethanol to give 9.0 9.
(79%) of 2-methyl-3-(4-methoxybenzoyl)-1-[2~ ipera-
zinyllethyl]-lH-indole dimethanesulEonate, m.p. 240C.
Examples 27B-27D
Following a procedure similar to that described in
Example 26A above, the following species of formula I were
similarly prepared:
Example 27B - 1-12-(2-hydroxyethylamino)ethyl]-2-methyl-3-
(4-m2thoxybenzoyl)-lH-indole, m p 99-lOO.SC. (14.2g.,
50%), prepared by saponification of 30.8 g. (0.08 mole) of
1-[2-(N-formyl-2-hydroxyethylamino)ethyl]-2-methyl-3-(4-
methoxybenzoyl)-lH-indole (Example 3AK) with 9.7 9. (0.243
mole) of sodium hydroxide in 160 ml. of water and 200 ml.
of ethanol;
Example 27C - 1-[2-(3-amino-1-piperidinyl)ethylJ-2-methyl-
3-(4-methoxybenzoyl)-lH-indole maleate (1:2), m.p. 142.5-
144~C. (1.5 g., 49~), prepared by saponiEication of 1.6 g.
(0.0026 mole) of 1-[2-(3-acetylamino-1-piperidinyl)ethyl]-
~ 7
-84-
2-methyl-3-(4-methoxybenzoyl)-lH-indole (E~ample 3N) with
1.6 y. (0.04 mole) of ~odium hydroxide in 2 ml. of water
and 6 ml. of ethylene ~lycol; and
Example 27D - 5-fluoro-2-methyl-3-~4-methoxybenzoyl)-1-[3-
~piperazinyl)~ropyl]-lH-indole di!nethanesulfonate, m.p.
114-115C (8.7 g., 27~), prepared by saponification of 23 g.
(0.053 mole) of 5-fluoro-1-[3-(4-formyl-l-pipera2inyl)-
propyl~-2-methyl-3-(4-methoxyben~oyl)-lH-indole (Example
3AL) with 5.6 g. (0.014 mole) of sodium hydroxide in 2~5
ml. of ethanol and 210 ml. of water.
ExamPle 28
To a solution containing 16.9 9. (0.04~ mole) of 1-
(3-b~omopropyl)-2-methyl-3-(4-methoxybenzoyl)-lH-illdole
(Preparation 7G) in 200 ml. of DMF was added 5 g. (0.088
mole) of azetidine. The mixture was stirred for about 24
hours at ambient temperature, then diluted with water and
extracted with ethyl acetate. The organic extracts were
washed with water, then with briner dried over magnesium
sulEate, filtered and taken to dryness. The residue was
taken into ethyl acetate, the solution diluted with
ethereal hydrogen chloride, and the solid which separated
was collected and recrystallized repeatedly from isopro-
panol to give 2.0 g. (10~) of 1-[3-(3-chloropropylamino)-
propyl]-2-methyl-3-~4-methoxyben o~L~lH-indole hydro-
chloride, m.p. 140-142C.
Example 29A
To a solution of 15~0 g. (0.032 mole) of 5-fluoro-2-
methyl-3-(4-methoxyben~oyl)-1-[3-(4-thiomorpholinyl)propyl]-
lH-indole hydrochloride (Example 3AF) in }95 ml. of glacial
s ~ ~
~25~C~7~i
-85-
acetic acid was added 8.12 g. (0.038 mole) oE an 80%
solution of m-chloroperbenzoic acid, and the solution was
stirred at ambient temperature for about forty-eight hours
and then poured into 300 ml. of ice water. The mixture was
treated with 1 9. of sodium bisulphite, basiEied with 35%
sodium hydroxide and then extracted with chloroform. The
organic extracts, on washing wi~th water, then with brine,
drying over sodium sulfate and evaporation to dryness
afforded 1.9 g. of the product as the free base which was
converted to the maleate salt by solution of the base in
ethyl acetate and addition of one equivalent of maleic
acid. The salt was recrystallized from ethanol to give
12.35 g. (72%) of 5-fluoro-2-methyl-3-(4-methoxybenzoy~
1-~3-(4-thiomorpholiny~Lp~opy~ H-indole S-oxide maleate,
m.p. 160-161C.
Examples 29B and 29C
Following a procedure similar to that described
in Ex~mple 29A above, the following species of formula
I were similarly prepared:
Exame~e 29B - 2-methyl-3-(4-methoxybenzoyl)-1-12-(4-thio-
morpholinyl)ethyl]-lH-indole S-oxide maleate, m.p. 179-
180C. (7.2 g., 82~), prepared by oxidation of 110 g. (0.028
mole) of 2-methyl-3-~4-methoxybenzoyl~-1-[2-t4-thiomorpho-
linyl)ethyl]-lH-indole (Example 3U) with 6.7 g~ (0.03 mole)
of m-chloroperbenzoic acid in 110 ml. of glacial acetic
acid; and
Example 29C - 2-methyl-3-(4-methoxybenzoyl)-1-[2-(4-thio-
morpholinyl)ethyl]-lH-indole_ S,N-dioxide dihydrate, m.p.
143-145C. (3.9 g., 27%), prepared by oxidation of 12.0 g.
~2~i;86~
-86-
(0.030 mole) of 2-methyl-3-(4-methoxybenzoyll-1-[2~(4-
thiomorpholinyl)ethyl]~lH-indole (Example 3U) with 6.6 g.
(0.030 mole) of m-chloroperbenzoic acid in 120 ml. of
chloroEorm.
Example 30
A solution of 28.7 9. (0.177 mole) of benzoyl-
acetone and 23.2 ml. ~0.177 mole) of 2-(4-morpholinyl)-
ethylamine in 600 ml. of toluene was heated under reflux
for ten and a half hours under a Dean-Stark trap and the
solution then cooled and taken to dryness to give N-[2-(4-
morpholinyl)ethyl]-N-(1-methyl-3-oxo-3 phenylpropenyl)amine
as a yellow solid.
The latter (11.3 g., 0.41 mole) and 8.9 g. (0.082
mole) of benzoquinone in 40 ml. of nitromethane was stirred
under nitrogen for forty-eight hours at room temperature
and the mixture then filtered through silica gel and the
filtrate adsorbed onto silica gel and flash chromatographed
using 5% acetone in ethyl acetate. The product was taken
ofE in the early and middle fractions which were taken to
dryness. The product was recrystallized first from ethyl
acetate and then from methanol to give 1.0 g. (7~) of 3-
benzoyl-5-hydroxy-2-methyl-1 [2-(4-morpholinyl)ethyl~-lH-
indole, m.p. 215-217C.
Example 31A
A solution of 13.4 g. ~0.0395 mole) of 5-fluoro-2-
methyl-3-(4-methoxybenzoyl)-1-~ 2,3-epoxy)propyl~-lH-indole
(Preparation 9A) and 4.79 g. (0.055 mole) oE morpholine in
60 ml. of chloroform was heated under reflux for about
Eorty-eight hours and then taken to dryness ln vacuo. The
crude product was dissolved in methylene dichloride, and
~2~
-87-
the solution was treated with an excess of ethereal
hydrogen chloride and then diluted with ether. The solid
which separated was collected and recrystallized from
methanol-ether to give 13.3 g. (61%) of 1-[2-hydroxy-3-~4-
S morpholinyl~ prop~-5- Eluo o-2-m thyl-3-~4-methoxybenzoyl~-
lH-indole hydrochloride hYdrate, (lHCl.l 1/4H20), m.p.
143-145C.
Examples 31B-31-0
Following a procedure similar to that described in
Example 31A above, reaction of a 1-11-(2,3-epoxy)propyl]-
3-R3-carbonyl-lH-indole with an amine, HN~B, aEforded the
following compounds oE formula Ib listed in Table 31,
where R2 in each instance is CH3.
~_ L . 1 3~A
`` ~2513~7~
--88--
~; ~
O ~ ~ a) ~z ' 5!; ~ .
` ~ -l b ~ o-
o O r~
T 'l ~ ~1 ~ t
o t~ a:~ er t.~l tr1 ~
~ ~ v
t o . ~x~ ~
~ ~ v ~
m ~ m a: m m ' m ~ m e~ m m
'V
E~~n v t~ a c~ a u ~ ~ Q Q ~ a .
U U 1~ U U ~ U g ~
z ,, ,, Z ~ ,, æ ,, ,, ~ Z Z Z Z 3 ~;
W ~ ~ ~ tV ~
U ~ U U ~ U V U UU U W C~ U ~N j~S
O O O O -V O O O O O O ~ O O ~
~ t,~ ~ tr~ ~ ~ t~ t~ t~ t~ tr) ~--) tr~ t~ tD
P~ m ~: m ~ 4
r ; y y y y ul C~ y y y ~?
~a ~3
W t,~ ", '~ ~ ~ tr, -/, ~ ~J
~;~51~1~7~
-8~-
Example 32
Following a procedure similar to that descrlbed
a~ove in Example 25A, 60 g. (0.165 mole) of 1-(3-azido-2-
hydroxy-l-propyl)-2-methyl-3-(4-methoxybenzoyl)-lH-indole
(Example 31J) in 500 ml. of ethanol was reduced with
hydrogen over 35 g. of palladium-on-barium sulfate
catalyst. The product was isolated in the form of the free
base and recrystallized from ethyl acetate to give 10.2 g.
(18%) of l-~3-amino-2-hydroxy-l-propyl)-2-methyl-3-(4
methoxybenzoyl)-lH-indole, m.p. 152-153C.
Example 33
The hydrobromide salt of 2-methyl-3-(4-methoxy-
benzoyl)-1-[2-(4-morpholinyl)ethyl]-lH-indole (Example lB)
(10.0 g., 0.026 mole) was prepared by passing hydrogen
bromide gas into a solution of the former in 200 ml. of
MDC. The hydrobromide was isolated, redissolved in 300 ml.
of ~DC and the solution treated with 6.94 9. (0.039 mole)
of N-bromosuccinimide. The solution was heated under
reflux and irradiated with light Eor twenty minutes, and
the solid which had separated was taken into chloroform-
ethyl acetate and the solution extracted with aqueous
potassium carbonate, dried over magnesium sulfate and taken
to dryness. The residue was chromatographed on silica gel,
the product being eluted with 25% acetone in toluene, which
was isolated and recrystallized from toluene to give 3.7 9.
(31~) of 5-bromo-2-methyl-3-(q-methylbenzoyl)-1-[2-~4-
morpholinyl)ethyl]-lH-indole m p 134 5-l36C
,
D~_. 7356A
--90--
Examples 34A-34H
Following a procedure similar to that described
in Example 2A above, it is contemplated that other species
of ~ormula I as follows can be prepared by reaction o~ a 2-
R2-1-[2-~4-morpholinyl)ethyl]-lH-indole with an ap-
propriate aroyl chloride (R3COCl) in the presence of alumi-
num chloride in methylene dichloride:
Example 34A - 2-methyl-1-[2-(4-morpholinyl)ethyl ? -3-(2-
quinolinecarbonyl)-lH-indole, by reaction of 2-methyl-
1-[2-(4-morpholinyl)ethyl]-lH-indole with 2-quinoline
carboxylic acid chloride;
- 2-methyl-1-[2-~4-morpholinyl)ethyl]-3-(3-
quinolinecarbonyl)-lH-indole, by reaction of 2-methyl-1-[2-
(4-morpholinyl)ethyl]-lH-indole with 3-quinoline carboxylic
acid chloride;
Example 34C - 2-methyl-1-[2-(4-morpholinyl)ethyl]-3-(4-
.
quinolinecarbonyl)-lH-indole, by reaction of 2-methyl-1-
~2-(4-morpholinyl)ethyl]-lH-indole with 4-quinoline carboxylic
acid chloride;
F.xample 34D - 2-methyl-1-[2-(4-mor~holinyl)ethy~]-3-(5-
quinolinecarbonyl)-lH-indole, by reaction o~ 2-methyl-
1-[2-(4-morpholinyl)ethyl]-lH-indole with 5-quinoline car-
boxylic acid chloride;
Example 34E - 2-methyl-1-[2-(4-morpholinyl)ethyl~-3-(6-
quinolinecarbonylL-lH-indole, by reaction of 2-methyl-
1-l2-(4 morpholi.nyl)ethyl]-l~-indole with 6-quinoline
carboxylic acid chloride;
D.~ 7356A
--91--
Example 34F - 2-methyl-1-[2-~4-morpholinyl~ yl]-3-(7-
qusnol;necarbonyl~-lH-indole, prepared by reaction of
2-methyl-1-[2-(4-morpholinyl)ethyl~-lH-indole with 7-
quinoline carboxylic acid chloride;
Example 34G - 2-methyl-1-[2-~4-morpholinYl)ethyl]-3-(8-
quinolinecarbonyl)-lH-indole, by reaction of 2-methyl-1-
l2-(4-morpholinyl)ethyl]-1~-indole with 8-quinoline car-
boxylic acid chloride; and
Example 34H - 2-benzyl-1-[2-(4-morpholinyl)ethyl]-3-(4-
methoxybenzoyl)-lH-indole, by reaction of 2-benzyl-1-[2-
(4-morpholinyl)ethyl]-lH-indole with 4-methoxybenzoyl
chloride.
D.~_J7356A
1258D70
-92-
BIOLOGICAL TEST RESULTS
The 3-~3-carbonyl-1-aminoalkyl-1~-indoles of
Formulas I, Ia and Ib of the invention were tested in the
acetylcholine-induced abdominal constriction test ~Ach),
the anti-bradykinin test ~BRDK) and the rat paw flexion
test (P.F.)~ all in vivo tests, and were found to have
analgesic activity. Data so-obtained are given:in Table B
below. Unless noted otherwise, all data were obtained on
oral administration and are expressed either as the ED50 or
as the percent inhibition at a given dose level (thus
30/]00 or 30% lnhibition at 100 mg./kg.)
In some instances, the compounds were retested
two or more times, and ED50 values were calculated for each
series of repeat tests. In such instances, each of the
ED50 values so-obtained is given in a series of values,
thus 6, 28, 3~, 43 in the case of the species of Example lAW
in the acetylcholine-induced abdominal constriction test.
~25~07~ -
--g3--
Table B
ExamEle AchBRDK P.F.
lA 73 56
LB 24,50,30,37 8.1 (LV.)
41,26,34,58
6.7 (LV.)
21,48 (~cO)
lC 126
lD 34,10,54,22 0/100 64
5.1 (iv.)
49 (~c.)
lE 0/100
lF 20 0/200 88/100
13 (LV.)
lG 84
0/3 (iv.)
50/qO (iv.)
100/30 (Lv,}
lH 33/100
71/300
0/3 (iv.)
30/10 (iv.)
100/30 (iv.)
Z/30 (~c.)
lI 75
8.5 (Lv.
lJ 86
6.7 (iv.)
lK 255
1-0/1 (iv.)
30/3 (iv.)
25/5.5 (iv.)
44/10 (LV )
1 M 50/100
lN 35.8
l-O 91.6
lP 40/100
4.5 (iv.)
lQ 7/24
27/79
60/23~
67/435
60/793
67/1~00
~2 5~ D .-l~,
_94_
Table B ~cont'~
Exa mFle Ach B R D K P.F.
lR 198
lS ~0 162
10/1 ~LV.)
20/3 ¦LV.)
100/10 (iv.)
lT 106
3.8 (iv.)
lU 155
.~V20/300
lW 0/30
40/300
47/550
10/1 (LV-)
0/1.73 (iv.)
86/3 (i.v.)
1 X 7/300
1 Y30/100
lZ 68
lAA10/100
lAB47/300
lA C 30 0/200 43/30
10/1.77 (LV.) 57/50
10/2.2 ~Lv.) 75/100
80/3 (LV.)
100/10 (:i.v.)
lAE 29 20/300 66~2
lAF 200
0/3 (iv.)
0/10 (LV.)
30/30 (i.v.)
lAG40/100
~7/300
10/10 (i~v.)
56/30 ~iv.)
20/30 (~c.)
lAH 85
lAI 74
lAJ13/100
53/300
lA K40/300
47/550
lAL 113
lA M 32
5 ~v.)
~25807~ D. ... 7356A
Table B (cont'~
E~am ~ Ach ~RD K P F.
1~ O 28 111 75/100
lAP 42 ~/50
33/200
6~/400
lA Q 53/300 0/10
17 (LV-) 12/30
12/100
lA R 27jl50
27/300
13/25 (~c.)
l~S 33/300
lAT 30 0/50,200
lAU 42 0/50
lAV 38 0/50
lA W 6,28,30,43 229 26
lAX 45 0/212
lAY 11,37,49 141 0/30,100
8.5 (iv.) 20/300
lAZ lOr27/50
20/75
73/100
53/150
lBA 197
IBB 97
IBC 40/100
lBD 65
lBE 50.9
lBF 0/30
lBG 33/300
lBH 0/30
27/100
53/300
58/550
7/30 (~c.)
50/10 (iv.)
lBI 13/300 0/6
27/100 (~c.)
0.69 (Lv.)
lBJ 0/100
lBL 0/100
lB M 0~100
lBN 36
lBO 173
18P 28
~ 2 ~ D. . 7356A
-96-
Takle B_~cont~
ExamF1e Ach BRDK ~.F.
.
LBR 123
lBT 90/100
~ W 10/100
1~ ~ 0/100
lCA 20/100
lCB 60/100
lCC 10/100
lC D 79
lCE 0/100
lCF 24
lCG 46.3
lC H 105
lCI 70/100
lCJ 56
lC K 30/100
lCL 30/100
2A 7/30
60/300
73/550
67/1000
2B 47/300
33/550
2C 19,33 0/30
3.3 (~v.) 60/300
2D 20~100
40/300
67/1000
2~ 33
2~ 20/30
40/100
33/300
2G 42
2H 49
ZI 28 132 62/100
~.6 tLV.)
18 (~c.)
2J 60
2L 10/100
2M 20/100
.
~5~ D~7~ v . 7356A
.
--97--
Ta~le B (cont'd)
ExamE~le Ach BR DK P.F.
2N 20/100
2-O 20/100
2P 30/100
2Q 20/100
2F~ 10/100
2S 0/100
2T 30/100
2U 88
2V 20/100
2W 72
2AB 91
2AC 30/100
2A D 10/100
2AE 20/100
2AF 30/100
2AG 143
2AH 20/100
2A K 30/0.3 (LV.)
2AL 20/O.l(iv.)
2AM ~0/100
2A N 90
2AO 40/100
2~P 27
2A R 50/100
2AT 20/100
2AU 30/100
2AV 10/100
2AW 20/100
2A X 0/100
2A Z 26
2BB 40/100
2BC 10/100
2B D 15
2BE 30/100
2BF 30/100
3~ 681
3B 26.5 ~8~310o
3C 53
-98 -
Tab~e B ~cont'd)
Examp~ Ach BRDK P.F.
3H 9.7(iv.)
3-l 30/100
3J 30/10 (LV.)
31~ 45,7
3L 44
3 M 10/100
3N 40/100
3-O 76
3P 71
3 Q 40/100
3R 40~100
3S 40/100
3T 53
3U 30/100
3V 253.8
3W ,~9
3Y 69
3AA 22
3AB 25
3AC 21
3AD 100/100
3AF 138.6
3AG 42
3A H 30/100
3AJ 35
4~ 15 53 0,12/100
4B 24,25,21,15 38,28,19 27.6
6 (iv.)
4C 37
4D 24
SA 31 0/300
20/1 (iv.)
29/3 (Lv.)
30/10 tLV.)
5B 25 61 0/10
1~/30
12/100
5C 19 20/30
60/100
60/300
5D 84 20/200
~7/3 (iv.)
29/1 (iv.)
79~ u,.
_99_
Table B (cont'd,)
Exam~le Ach B~D K P.F~
5E 38/150
40/300
5F 76
6 83 0/100
0/10 (iv.) 0/300
0/30 ~iv.)
13/30 (~c.)
7 40 0/300
8A 32 62/30
3B 35~100
9 27/300
20/30 (~c.)
0/30
7/30 (~c.)
11 20/30
13/30 (~c.)
12 13/30
0/3U
13A 139
13~ 0/100
13C 20/100
14 40/100
155
16A 10/100
16B 20/100
17 7/3~ 33/100 (s.c.)
6.6 (~c.)
18 30/100
19 40/100
20A 128
20B 40~100
21 31
22 66.8
23A 85
23B 39
25A Ir) 82.5
25B 42
26A 40/100
26B 40/100
26C 30/100
26D 30/100
26E 73.1
26F 61
~5~7~ -~
~100 -
Tal~Le B (oont'd.)
Exam~ Ach BRDX P.F.
26G 20/100
27A 20.7
27B 59.8
27C 29.4
27 D 30
28 90/100
29~ 60,80/100
29B 60~70/100
29C 0/100
10/100
31A 58
31C 53
31F 0/3 (iV~
31G 133
31H 56
30/100(iC.V.)
80/10 (iV.)
31-I 31,40,88/100
31J 10/100
31K 28
31L 32
31 M 26
312~ 90,100/100
31-O 100~100
32 85
33 20/100
(r) N=B is amino
The 3-R3-carbonyl-1-aminoaLcyl-lH-indciles of formulas I, Ia and Ib of the
invention were also tested in the develcp~ng adj~lvant arthritic assay, the pd~sma
fibronec~ assay and the pleurisy macrophage assay in rats Data ~abtained,
expre~;ed as p values as a measure of the sta'cistical s~gnificance of the resul s
for each of the parameters measured, ie. inhibition of in~lammation oE non-
ir~ected paw (N~?) and i~ected paw ~right paw vaaume or RPV), lowering of
~sma fibronectin levels p~N) and inhibition of macrophage accumul~tion in the
p~eural cavity (MAC), are given in Table C. Compa~nds were cons~dered active
at p < 0.05 levels Non statistically si~nificant res iLts are recorded as 1~_11.
..
-101-
TabLe C
xampJ~ NIP _ FN MAC
lB ~ 0.01 0.01
lF 0.01 0.01
~I 0.01 0.01 0.01 0.01
lU
lAC _ _
lAO
lAP
lAW
lBA - - 0.01
lBB
lBD
lBE _ 0 05
lBL 0.01 0.05 0.01
lB M 0.01 0.01 0.01 0.01
lBN
lB O - 0.01 O.OS
lBP 0.01 0.01
lB Q (~ 0.01 0.01 0.01 0.01
lB R 0.01 0.01 0.01
lB Z 0.05 0.01 0.01
lCC
lCE
lCF 0.01 0.01
lCG 0.01 0.01 0.01
lCH
lCJ 0.01 0.01 - -
lCL - - 0.01
lC M - 0.01
lC O 0.01 0.01
lCP 0.01 0.01 0.01 0.01
2C 0.01 0.01 0.01 0.01
2E 0.01 0.01 - -
2R - _ _
~5 -- _ _
2U - - 0.01
2V
2Y 0.05 -
~25~ 7q3 ~ 13~6~
-102--
Ta~le C (contd.)
Exampd~ _ RPV FN MAC
2AA
2AB
2AC 0.05 _ _
2AD
2AE 0.01 0.01
2AF 0.01 0.01
2AG OeOl ~ O~Ol
2AI 0.01 0.01 0.0
2AK
2AN - _ _
2A O 0.01 0.01 0.01 0.05
2AQ
2AS
2AT - - -
2AU - _ 0 05
2AV
2AW - _ _ 0 05
2~X -- _ .
2AY 0.01 0.05
2BB - 0.01 0.05
2BF . - 0.01 0.01
3D
3E 0.01
3F 0.05 0.01
3G
3 K - 0.01 0.05
3T - 0.01
3U
3 W 0.01 0.01 O.OS
3AF - 0.01
3A G 0.01 0.01 0.01
3AH 0.01 - 0.01
3AI 0.01 0.01, 0.05
3P~J 0.01 0.01 0.05
~; - - 0.05
13B - - 0.01
13C
..,
D ~ ~ ~ L~
2 5~70
--103--
TableC (conta3.)
ExamFiLe N~? RPV FN MAC
16A 0.05 - - .
19 -- _ _
20A - _ o 05
20B
21
22 0.01 0.01 - 0.05
23A 0.01 0.01 0.01
23B 0.01 0.01 0.01
24 0.05 0.01
25A
25B
26E
26F 0.05 0.01 ~-
26 G - - 0.01
27A O.OS 0.01
27B 0.05 0.01
27 D 0.01 0.01
29A OqOS 0.01
29B
31A 0.01 O.IJl
31B 0.1~1 -
31H 0.01
31J 0.05
31L 0.05 0.01
31M 0.01 - 0.01
31N 0.01 0.01
31-O 0.01 0.01
32 0.01 0.01 0.05
(s) The maleate sal~
(t) The lower m ELt~ng pciLymorph
Certain species of the ~ntermediate 2-R2-3-(R3~arbony~-indcdes o
Eormu~ D: were a~ tested and found active in one or more oE the
acetvlchcdine-induced abdominal constrk:tion test (Ach), the devek~p~ng
adjuvant arthritic a~ay ~NIP and RPV), ~e ~ibronectin assa~ (FN) and
the EilQurisy macrophage a~3ay (MAC). Data g~obtained, expressed as
desc ribed above, are given in Table D.
~l2S~
-lo 4-
Tatile D
PreE~n. Ach ~I:P RPV FN MAC
lF 0/100 - - -
lAJ
lA R 20/100 - - - 0~05
lAL 20/100 0.01 - 0.01 0.01
lA M - - O.t)l
lAN 0.01 0.01 - -
lA O 40/100
lA O 0.01 0.01 0.01
Certain species of the intermediate 2-R2-1-aminoaLcyl-lH-~ndc~es of
~ormula Irl were tested and found active in the acetylchc~ine-induced
abdominal constrictLon test. Thus 2-methyl-1-[1-methyl-2-(4-mcrph~
linyl~ethyl]-lH-indole methanesul~onate hydrate (Preparation 5A) pr~
duced 40 ~ inhibit~on at 300 mg./kg. ~o.), and the ED50 oE 5-1uoro-2-
methyl-l~ methyl-2~imethylaminoe~yll-lH indc~e (Preparation ~)
was found to be 25 mg./kg. ~? )-
